top of page
Ref 473
Ref 428
Ref 355
Ref 186

References

  1.  Altman DG. Better reporting of randomised controlled trials: the CONSORT statement. BMJ 1996;313:570-1. PubMed doi:10.1136/bmj.313.7057.570

  2. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet 2014;383:267-76. PubMed doi:10.1016/S0140-6736(13)62228-X

  3. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 2012;11:MR000030. PubMed doi:10.1002/14651858.MR000030.pub2

  4. Savović J, Jones HE, Altman DG, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012;157:429-38. PubMed doi:10.7326/0003-4819-157-6-201209180-00537

  5. Goldacre B, Drysdale H, Powell-Smith A, et al. The COMPare Trials Project. https://www.compare-trials.org/ 2016

  6. Andrew E, Anis A, Chalmers T, et al; The Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. JAMA 1994;272:1926-31. PubMed doi:10.1001/jama.1994.03520240054041

  7. The Asilomar Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature. Checklist of information for inclusion in reports of clinical trials. Ann Intern Med 1996;124:741-3. PubMed doi:10.7326/0003-4819-124-8-199604150-00007

  8. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9. PubMed doi:10.1001/jama.1996.03540080059030

  9. Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91. PubMed doi:10.1001/jama.285.15.1987

  10. Altman DG, Schulz KF, Moher D, et al; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94. PubMed doi:10.7326/0003-4819-134-8-200104170-00012

  11. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. PubMed doi:10.1136/bmj.c332

  12. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. PubMed doi:10.1136/bmj.c869

  13. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200-7. PubMed doi:10.7326/0003-4819-158-3-201302050-00583

  14. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. PubMed doi:10.1136/bmj.e7586

  15. Hopewell S, Boutron I, Chan A-W, et al. An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials. Nat Med 2022;28:1740-3. PubMed doi:10.1038/s41591-022-01989-8

  16. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med 2010;7:e1000217. PubMed doi:10.1371/journal.pmed.1000217

  17. Tunn R, Boutron I, Chan AW, et al. Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements. J Clin Epidemiol 2024;169:111309. PubMed doi:10.1016/j.jclinepi.2024.111309

  18. Nejstgaard CH, Boutron I, Chan AW, et al. A scoping review identifies multiple comments suggesting modifications to SPIRIT 2013 and CONSORT 2010. J Clin Epidemiol 2023;155:48-63. PubMed doi:10.1016/j.jclinepi.2023.01.003

  19. Østengaard L, Barrientos A, Boutron I, et al. Development of a topic-specific bibliographic database supporting the updates of SPIRIT 2013 and CONSORT 2010. Cochrane Evidence Synthesis and Methods 2024;2:e12057 doi:10.1002/cesm.12057

  20. Junqueira DR, Zorzela L, Golder S, et al; CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ 2023;381:e073725. PubMed doi:10.1136/bmj-2022-073725

  21. Butcher NJ, Monsour A, Mew EJ, et al. Guidelines for reporting outcomes in trial reports: The CONSORT-Outcomes 2022 extension. JAMA 2022;328:2252-64. PubMed doi:10.1001/jama.2022.21022

  22.  Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. Ann Intern Med 2017;167:40-7. PubMed doi:10.7326/M17-0046

  23. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687. PubMed doi:10.1136/bmj.g1687

  24. Hopewell S, Chan A-W, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ 2025;388:e081123. doi:10.1136/bmj-2024-081123

  25. Bouzat P, Charbit J, Abback P-S, et al; PROCOAG Study Group. Efficacy and safety of early administration of 4-factor prothrombin complex concentrate in patients with trauma at risk of massive transfusion: the PROCOAG randomized clinical trial. JAMA 2023;329:1367-75. PubMed doi:10.1001/jama.2023.4080

  26. Dickersin K, Manheimer E, Wieland S, Robinson KA, Lefebvre C, McDonald S. Development of the Cochrane Collaboration’s CENTRAL Register of controlled clinical trials. Eval Health Prof 2002;25:38-64. PubMed

  27.  PLoS Medicine Editors. The impact of open access upon public health. PLoS Med 2006;3:e252. PubMed doi:10.1371/journal.pmed.0030252

  28. Harbourt AM, Knecht LS, Humphreys BL. Structured abstracts in MEDLINE, 1989-1991. Bull Med Libr Assoc 1995;83:190-5. PubMed

  29. Harris AHS, Standard S, Brunning JL, et al. The accuracy of abstracts in psychology journals. J Psychol 2002;136:141-8. PubMed doi:10.1080/00223980209604145

  30. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA 1999;281:1110-1. PubMed doi:10.1001/jama.281.12.1110

  31. Ward LG, Kendrach MG, Price SO. Accuracy of abstracts for original research articles in pharmacy journals. Ann Pharmacother 2004;38:1173-7. PubMed doi:10.1345/aph.1D416

  32. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross sectional study. BMJ 2006;333:231-4. PubMed doi:10.1136/bmj.38895.410451.79

  33. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303:2058-64. PubMed doi:10.1001/jama.2010.651

  34. Chiu K, Grundy Q, Bero L. ‘Spin’ in published biomedical literature: A methodological systematic review. PLoS Biol 2017;15:e2002173. PubMed doi:10.1371/journal.pbio.2002173

  35. Spungen H, Burton J, Schenkel S, Schriger DL. Completeness and Spin of medRxiv Preprint and Associated Published Abstracts of COVID-19 Randomized Clinical Trials. JAMA 2023;329:1310-2. PubMed doi:10.1001/jama.2023.1784

  36. Ioannidis JPA, Evans SJW, Gøtzsche PC, et al; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8. PubMed doi:10.7326/0003-4819-141-10-200411160-00009

  37. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437-43. PubMed doi:10.1001/jama.285.4.437

  38. Hopewell S, Clarke M, Moher D, et al; CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med 2008;5:e20. PubMed doi:10.1371/journal.pmed.0050020

  39. Chhapola V, Tiwari S, Brar R, Kanwal SK. Reporting quality of trial abstracts-improved yet suboptimal: A systematic review and meta-analysis. J Evid Based Med 2018;11:89-94. PubMed doi:10.1111/jebm.12294

  40. Hopewell S, Clarke M, Moher D, et al; CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med 2008;5:e20. PubMed doi:10.1371/journal.pmed.0050020

  41. Haynes RB, Mulrow CD, Huth EJ, Altman DG, Gardner MJ. More informative abstracts revisited. Ann Intern Med 1990;113:69-76. PubMed doi:10.7326/0003-4819-113-1-69

  42. Taddio A, Pain T, Fassos FF, Boon H, Ilersich AL, Einarson TR. Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association. CMAJ 1994;150:1611-5. PubMed

  43. Wager E, Middleton P. Technical editing of research reports in biomedical journals. Cochrane Database Syst Rev 2008;2008:MR000002. PubMed doi:10.1002/14651858.MR000002.pub3

  44. Hartley J, Sydes M, Blurton A. Obtaining information accurately and quickly: are structured abstracts more efficient? J Inf Sci 1996;22:349-56 doi:10.1177/016555159602200503 

  45. UNESCO. UNESCO Recommendation on Open Science. https://unesdoc.unesco.org/ark:/48223/pf0000379949. 2021

  46. Ganjavi C, Eppler MB, Pekcan A, et al. Publishers’ and journals’ instructions to authors on use of generative artificial intelligence in academic and scientific publishing: bibliometric analysis. BMJ 2024;384:e077192. PubMed doi:10.1136/bmj-2023-077192

  47. Nazari M, Shabani R, Hassanzadeh-Rad A, Esfandiari MA, Dalili S. Effect of concurrent resistance-aerobic training on inflammatory factors and growth hormones in children with type 1 diabetes: a randomized controlled clinical trial. Trials 2023;24:519. PubMed doi:10.1186/s13063-023-07553-0

  48. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev 1997;9(Suppl):15-21. PubMed

  49. Alayche M, Cobey KD, Ng JY, et al. Evaluating prospective study registration and result reporting of trials conducted in Canada from 2009 to 2019. Facets 2023;8:1-10 doi:10.1139/facets-2022-0208.

  50. Riedel N, Wieschowski S, Bruckner T, et al. Results dissemination from completed clinical trials conducted at German university medical centers remained delayed and incomplete. The 2014 -2017 cohort. J Clin Epidemiol 2022;144:1-7. PubMed doi:10.1016/j.jclinepi.2021.12.012

  51. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65. PubMed doi:10.1001/jama.291.20.2457

  52. Al-Marzouki S, Roberts I, Evans S, Marshall T. Selective reporting in clinical trials: analysis of trial protocols accepted by The Lancet. Lancet 2008;372:201. PubMed doi:10.1016/S0140-6736(08)61060-0

  53. Williamson PR, Gamble C. Identification and impact of outcome selection bias in meta-analysis. Stat Med 2005;24:1547-61. PubMed doi:10.1002/sim.2025

  54. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986;4:1529-41. PubMed doi:10.1200/JCO.1986.4.10.1529

  55. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med 2006;99:337-41. PubMed doi:10.1177/014107680609900715

  56. Tonks A. A clinical trials register for Europe. BMJ 2002;325:1314-5. PubMed doi:10.1136/bmj.325.7376.1314

  57. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003;290:516-23. PubMed doi:10.1001/jama.290.4.516

  58. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5. PubMed doi:10.1016/S0140-6736(04)16043-1

  59. World Health Organization. International standards for clinical trial registries: the registration of all interventional trials is a scientific, ethical and moral responsibility. 3rd ed. World Health Organization, 2018

  60. De Angelis CD, Drazen JM, Frizelle FA, et al; International Committee of Medical Journal Editors. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet 2005;365:1827-9. PubMed doi:10.1016/S0140-6736(05)66588-9

  61. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DAB. Issues in the registration of clinical trials. JAMA 2007;297:2112-20. PubMed doi:10.1001/jama.297.19.2112

  62. Nosek BA, Alter G, Banks GC, et al. SCIENTIFIC STANDARDS. Promoting an open research culture. Science 2015;348:1422-5. PubMed doi:10.1126/science.aab2374

  63. Shamseer L, Hopewell S, Altman DG, Moher D, Schulz KF. Update on the endorsement of CONSORT by high impact factor journals: a survey of journal “Instructions to Authors” in 2014. Trials 2016;17:301. PubMed doi:10.1186/s13063-016-1408-z

  64. Lombard N, Gasmi A, Sulpice L, Boudjema K, Naudet F, Bergeat D. Research transparency promotion by surgical journals publishing randomised controlled trials: a survey. Trials 2020;21:824. PubMed doi:10.1186/s13063-020-04756-7

  65. Trinquart L, Dunn AG, Bourgeois FT. Registration of published randomized trials: a systematic review and meta-analysis. BMC Med 2018;16:173. PubMed doi:10.1186/s12916-018-1168-6

  66. Chan A-W, Pello A, Kitchen J, et al. Association of Trial Registration With Reporting of Primary Outcomes in Protocols and Publications. JAMA 2017;318:1709-11. PubMed doi:10.1001/jama.2017.13001

  67. Chan AW, Song F, Vickers A, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet 2014;383:257-66. PubMed doi:10.1016/S0140-6736(13)62296-5

  68. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet 2020;395:361-9. PubMed doi:10.1016/S0140-6736(19)33220-9

  69. DeVito NJ, Morley J, Smith JA, Drysdale H, Goldacre B, Heneghan C. Availability of results of clinical trials registered on EU Clinical Trials Register: cross sectional audit study. BMJ Med 2024;3:e000738. PubMed doi:10.1136/bmjmed-2023-000738

  70. Pellat A, Boutron I, Ravaud P. Availability of Results of Trials Studying Pancreatic Adenocarcinoma over the Past 10 Years. Oncologist 2022;27:e849-55. PubMed doi:10.1093/oncolo/oyac156

  71. Moorthy VS, Karam G, Vannice KS, Kieny MP. Rationale for WHO’s new position calling for prompt reporting and public disclosure of interventional clinical trial results. PLoS Med 2015;12:e1001819. PubMed doi:10.1371/journal.pmed.1001819

  72. Food and Drug Administration Amendments Act of 2007. Public Law 110-85. https://www.govinfo.gov/app/details/PLAW-110publ85d [accessed 17 September 2024]. 2007.

  73. European Commission. Commission Guideline — Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006. Official J Eur Union. 2012;55:7-10.

  74. Gross O, Tönshoff B, Weber LT, et al; German Pediatric Nephrology (GPN) Study Group and EARLY PRO-TECT Alport Investigators. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int 2020;97:1275-86. PubMed doi:10.1016/j.kint.2019.12.015

  75. Goldacre B, Drysdale H, Dale A, et al. COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time. Trials 2019;20:118. PubMed doi:10.1186/s13063-019-3173-2

  76. Goldacre B, Drysdale H, Marston C, et al. COMPare: Qualitative analysis of researchers’ responses to critical correspondence on a cohort of 58 misreported trials. Trials 2019;20:124. PubMed doi:10.1186/s13063-019-3172-3

  77. Chan A-W, Hróbjartsson A. Promoting public access to clinical trial protocols: challenges and recommendations. Trials 2018;19:116. PubMed doi:10.1186/s13063-018-2510-1

  78. Chan A-W, Boutron I, Hopewell S, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ 2025;388:e081477. doi:10.1136/bmj-2024-081477

  79. Gamble C, Krishan A, Stocken D, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA 2017;318:2337-43. PubMed doi:10.1001/jama.2017.18556

  80. Rangan A, Brealey SD, Keding A, et al; UK FROST Study Group. Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial. Lancet 2020;396:977-89. PubMed doi:10.1016/S0140-6736(20)31965-6

  81. Roaldsen MB, Eltoft A, Wilsgaard T, et al; TWIST Investigators. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurol 2023;22:117-26. PubMed doi:10.1016/S1474-4422(22)00484-7

  82. Colavizza G, Hrynaszkiewicz I, Staden I, Whitaker K, McGillivray B. The citation advantage of linking publications to research data. PLoS One 2020;15:e0230416. PubMed doi:10.1371/journal.pone.0230416

  83. Stewart LA, Clarke M, Rovers M, et al; PRISMA-IPD Development Group. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA 2015;313:1657-65. PubMed doi:10.1001/jama.2015.3656

  84. Naudet F, Sakarovitch C, Janiaud P, et al. Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS Medicine. BMJ 2018;360:k400. PubMed doi:10.1136/bmj.k400

  85. Bergeat D, Lombard N, Gasmi A, Le Floch B, Naudet F. Data sharing and reanalyses among randomized clinical trials published in surgical journals before and after adoption of a data availability and reproducibility policy. JAMA Netw Open 2022;5:e2215209. PubMed doi:10.1001/jamanetworkopen.2022.15209

  86. Rowhani-Farid A, Grewal M, Solar S, et al. Clinical trial data sharing: a cross-sectional study of outcomes associated with two U.S. National Institutes of Health models. Sci Data 2023;10:529. PubMed doi:10.1038/s41597-023-02436-0

  87. Esmail LC, Kapp P, Assi R, et al. Sharing of individual patient-level data by trialists of randomized clinical trials of pharmacological treatments for COVID-19. JAMA 2023;329:1695-7. PubMed doi:10.1001/jama.2023.4590

  88. Ohmann C, Moher D, Siebert M, Motschall E, Naudet F. Status, use and impact of sharing individual participant data from clinical trials: a scoping review. BMJ Open 2021;11:e049228. PubMed doi:10.1136/bmjopen-2021-049228

  89. Larregue J, Vincent-Lamarre P, Lebaron F, Larivière V. COVID-19: Where is the data? LSE Impact Blog, 30 novembre 2020. https://unesco.ebsi.umontreal.ca/en/publications/covid-19-where-is-the-data/

  90. Ioannidis JPA. Hundreds of thousands of zombie randomised trials circulate among us. Anaesthesia 2021;76:444-7. PubMed doi:10.1111/anae.15297

  91. Carlisle JB. False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. Anaesthesia 2021;76:472-9. PubMed doi:10.1111/anae.15263

  92. Pellen C, Le Louarn A, Spurrier-Bernard G, et al. Ten (not so) simple rules for clinical trial data-sharing. PLoS Comput Biol 2023;19:e1010879. PubMed doi:10.1371/journal.pcbi.1010879

  93. Tudor Smith C, Hopkins C, Sydes M, et al. Good Practice Principles for Sharing Individual Participant Data from Publicly Funded Clinical Trials. https://www.methodologyhubs.mrc.ac.uk/files/7114/3682/3831/Datasharingguidance2015.pdf [accessed 15 April 2024]. 2015.

  94. The White House. OSTP Issues Guidance to Make Federally Funded Research Freely Available Without Delay. https://www.whitehouse.gov/ostp/news-updates/2022/08/25/ostp-issues-guidance-to-make-federally-funded-research-freely-available-without-delay/ [accessed 17 September 2024]. 2022.

  95. National Institutes of Health. Data management and sharing policy. https://sharing.nih.gov/data-management-and-sharing-policy/data-management#:~:text=NIH%20encourages%20data%20management%20and,repurposing%20datasets%20for%20secondary%20research. [Accessed 29 Jan 2024]

  96. Siebert M, Ioannidis JPA. Lifting of Embargoes to Data Sharing in Clinical Trials Published in Top Medical Journals. JAMA 2024;331:354-5. PubMed doi:10.1001/jama.2023.25394

  97. Gregson S, Adamson S, Papaya S, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med 2007;4:e102. PubMed doi:10.1371/journal.pmed.0040102

  98. Rha SY, Oh DY, Yañez P, et al; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023;24:1181-95. PubMed doi:10.1016/S1470-2045(23)00515-6

  99. Speich B, von Niederhäusern B, Schur N, et al; MAking Randomized Trials Affordable (MARTA) Group. Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. J Clin Epidemiol 2018;96:1-11. PubMed doi:10.1016/j.jclinepi.2017.12.018

  100. Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost? Nat Rev Drug Discov 2017;16:381-2. PubMed doi:10.1038/nrd.2017.70

  101. Raftery J, Young A, Stanton L, et al. Clinical trial metadata: defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme. Health Technol Assess 2015;19:1-138. PubMed doi:10.3310/hta19110

  102. Rasmussen K, Bero L, Redberg R, Gøtzsche PC, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ 2018;363:k3654. PubMed doi:10.1136/bmj.k3654

  103. Siena LM, Papamanolis L, Siebert MJ, Bellomo RK, Ioannidis JPA. Industry Involvement and Transparency in the Most Cited Clinical Trials, 2019-2022. JAMA Netw Open 2023;6:e2343425. PubMed doi:10.1001/jamanetworkopen.2023.43425

  104. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033. PubMed

  105. Nejstgaard CH, Laursen DRT, Lundh A, Hróbjartsson A. Commercial funding and estimated intervention effects in randomized clinical trials: Systematic review of meta-epidemiological studies. Res Synth Methods 2023;14:144-55. PubMed doi:10.1002/jrsm.1611

  106. Østengaard L, Lundh A, Tjørnhøj-Thomsen T, et al. Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study. BMJ 2020;371:m3764. PubMed doi:10.1136/bmj.m3764

  107. Hakoum MB, Jouni N, Abou-Jaoude EA, et al. Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance. BMJ Open 2017;7:e015997. PubMed doi:10.1136/bmjopen-2017-015997

  108. Institute of Medicine. Conflict of interest in medical research, education, and practice. National Academies Press, 2009.

  109. Hakoum MB, Jouni N, Abou-Jaoude EA, et al. Authors of clinical trials reported individual and financial conflicts of interest more frequently than institutional and nonfinancial ones: a methodological survey. J Clin Epidemiol 2017;87:78-86. PubMed doi:10.1016/j.jclinepi.2017.04.002

  110. Lenzer J. When is a point of view a conflict of interest? BMJ 2016;355:i6194. PubMed doi:10.1136/bmj.i6194

  111. Ahn R, Woodbridge A, Abraham A, et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. BMJ 2017;356:i6770. PubMed doi:10.1136/bmj.i6770

  112. El-Rayess H, Khamis AM, Haddad S, et al. Assessing concordance of financial conflicts of interest disclosures with payments’ databases: a systematic survey of the health literature. J Clin Epidemiol 2020;127:19-28. PubMed doi:10.1016/j.jclinepi.2020.06.040

  113. Rasmussen K, Schroll J, Gøtzsche PC, Lundh A. Under-reporting of conflicts of interest among trialists: a cross-sectional study. J R Soc Med 2015;108:101-7. PubMed doi:10.1177/0141076814557878

  114. Hopewell S, Keene DJ, Marian IR, et al; GRASP Trial Group. Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial. Lancet 2021;398:416-28. PubMed doi:10.1016/S0140-6736(21)00846-1

  115. Dawson L, Zarin DA, Emanuel EJ, Friedman LM, Chaudhari B, Goodman SN. Considering usual medical care in clinical trial design. PLoS Med 2009;6:e1000111. PubMed doi:10.1371/journal.pmed.1000111

  116. van Luijn JC, van Loenen AC, Gribnau FW, Leufkens HG. Choice of comparator in active control trials of new drugs. Ann Pharmacother 2008;42:1605-12. PubMed doi:10.1345/aph.1L115

  117. World Medical Association Declaration of Helsinki. ethical principle for medical research involving human participants. 75th WMA General Assembly, Finland, 2024. https://www.wma.net/policies-post/wma-declaration-of-helsinki/ (accessed 10 February 2025).

  118. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-54. PubMed doi:10.1056/NEJM199207233270406

  119. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005;2:218-29, discussion 229-32. PubMed doi:10.1191/1740774505cn085oa

  120. Clarke M, Brice A, Chalmers I. Accumulating research: a systematic account of how cumulative meta-analyses would have provided knowledge, improved health, reduced harm and saved resources. PLoS One 2014;9:e102670. PubMed doi:10.1371/journal.pone.0102670

  121. Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ 1996;313:1390-3. PubMed doi:10.1136/bmj.313.7069.1390

  122. Jia Y, Li B, Yang Z, et al. Trends of randomized clinical trials citing prior systematic reviews, 2007-2021. JAMA Netw Open 2023;6:e234219. PubMed doi:10.1001/jamanetworkopen.2023.4219

  123. Bruce J, Mazuquin B, Canaway A, et al; Prevention of Shoulder Problems Trial (PROSPER) Study Group. Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation. BMJ 2021;375:e066542. PubMed doi:10.1136/bmj-2021-066542

  124. AHRQ. Using the PICOTS Framework to Strengthen Evidence Gathered in Clinical Trials—Guidance from the AHRQ’s Evidence-based Practice Centers Program. Available at: https://www.fda.gov/media/109448/download [accessed 13 March 2024].

  125. Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med 2016;13:e1002127. PubMed doi:10.1371/journal.pmed.1002127

  126. Lineberry N, Berlin JA, Mansi B, et al. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ 2016;355:i5078. PubMed doi:10.1136/bmj.i5078

  127. Junqueira DR, Phillips R, Zorzela L, et al. Time to improve the reporting of harms in randomized controlled trials. J Clin Epidemiol 2021;136:216-20. PubMed doi:10.1016/j.jclinepi.2021.04.020

  128. Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open 2019;9:e024537. PubMed doi:10.1136/bmjopen-2018-024537

  129. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012;308:2594-604. PubMed doi:10.1001/jama.2012.87802

  130. Eldridge SM, Chan CL, Campbell MJ, et al; PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ 2016;355:i5239. PubMed doi:10.1136/bmj.i5239

  131. Park JJH, Harari O, Dron L, Lester RT, Thorlund K, Mills EJ. An overview of platform trials with a checklist for clinical readers. J Clin Epidemiol 2020;125:1-8. PubMed doi:10.1016/j.jclinepi.2020.04.025

  132. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol 2009;62:499-505. PubMed doi:10.1016/j.jclinepi.2009.01.012

  133. Fleming TR. Clinical trials: discerning hype from substance. Ann Intern Med 2010;153:400-6. PubMed doi:10.7326/0003-4819-153-6-201009210-00008

  134. Cro S, Kahan BC, Rehal S, et al. Evaluating how clear the questions being investigated in randomised trials are: systematic review of estimands. BMJ 2022;378:e070146. PubMed doi:10.1136/bmj-2022-070146

  135. Kahan BC, Hindley J, Edwards M, Cro S, Morris TP. The estimands framework: a primer on the ICH E9(R1) addendum. BMJ 2024;384:e076316. PubMed doi:10.1136/bmj-2023-076316

  136. European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Available at: https://www.ema.europa.eu/en/ documents/scientific-guideline/ich-e9-r1-addendum-estimands- sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf. 2020.

  137. Homer V, Yap C, Bond S, et al. Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ 2022;376:e068177. PubMed doi:10.1136/bmj-2021-068177

  138. Kahan BC, Hall SS, Beller EM, et al. Reporting of factorial randomized trials: extension of the CONSORT 2010 statement. JAMA 2023;330:2106-14. PubMed doi:10.1001/jama.2023.19793

  139. Kahan BC, Hall SS, Beller EM, et al. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Netw Open 2023;6:e2346121. PubMed doi:10.1001/jamanetworkopen.2023.46121

  140. Paskins Z, Bromley K, Lewis M, et al. Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial. BMJ 2022;377:e068446. PubMed doi:10.1136/bmj-2021-068446

  141. Costa ML, Achten J, Ooms A, et al; DRAFFT2 Collaborators. Surgical fixation with K-wires versus casting in adults with fracture of distal radius: DRAFFT2 multicentre randomised clinical trial. BMJ 2022;376:e068041. PubMed doi:10.1136/bmj-2021-068041

  142. Edwardson CL, Biddle SJH, Clemes SA, et al. Effectiveness of an intervention for reducing sitting time and improving health in office workers: three arm cluster randomised controlled trial. BMJ 2022;378:e069288. PubMed doi:10.1136/bmj-2021-069288

  143. INSPIRATION-S Investigators. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ 2022;376:e068407. PubMed

  144. Staley K. Exploring impact: public involvement in NHS, public health and social care research. INVOLVE, Eastleigh. https://wellcomecollection.org/works/wtbmggvr. 2009.

  145. Price A, Albarqouni L, Kirkpatrick J, et al. Patient and public involvement in the design of clinical trials: An overview of systematic reviews. J Eval Clin Pract 2018;24:240-53. PubMed doi:10.1111/jep.12805

  146. National Institute for Health and Care Research. Briefing notes for researchers - public involvement in NHS, health and social care research (version 1.0) [Accessed 11 Sept 2023] 2021

  147. Forsythe LP, Carman KL, Szydlowski V, et al. Patient engagement in research: early findings from the Patient-Centered Outcomes Research Institute. Health Aff (Millwood) 2019;38:359-67. PubMed doi:10.1377/hlthaff.2018.05067

  148. Vanderhout S, Nicholls S, Monfaredi Z, et al. Facilitating and supporting the engagement of patients, families and caregivers in research: the “Ottawa model” for patient engagement in research. Res Involv Engagem 2022;8:25. PubMed doi:10.1186/s40900-022-00350-0

  149. NHMRC. Guidelines for Guidelines: Consumer involvement. https://www.nhmrc.gov.au/guidelinesforguidelines/plan/consumer-involvement. 2018. [Accessed 11 Sept 2023]

  150. Staniszewska S, Brett J, Mockford C, Barber R. The GRIPP checklist: strengthening the quality of patient and public involvement reporting in research. Int J Technol Assess Health Care 2011;27:391-9. PubMed doi:10.1017/S0266462311000481

  151. Staniszewska S, Brett J, Simera I, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. BMJ 2017;358:j3453. PubMed doi:10.1136/bmj.j3453

  152. NHMRC. Statement on Consumer and Community involvement in Health and Medical Research. https://www.nhmrc.gov.au/sites/default/files/documents/reports/consumer-community-involvement.pdf [Accessed 09 Sept 2023]: Consumers Health Forum of Australia; 2016

  153. CIHR-IRSC. Strategy for Patient-Oriented Research patient engagement framework. 2019. https://cihr-irsc.gc.ca/e/documents/spor_framework-en.pdf [Accessed 09 Sept 2023]

  154. Richards T, Godlee F. The BMJ’s own patient journey. BMJ 2014;348:g3726. PubMed doi:10.1136/bmj.g3726

  155. BMJ. New requirements for patient and public involvement statements in BMJ Open. 2018. https://blogs.bmj.com/bmjopen/2018/03/23/new-requirements-for-patient-and-public-involvement-statements-in-bmj-open/ [Accessed 09 Sept 2023].

  156. BMJ. BMJ author hub: patient and public partnership. https://authors.bmj.com/policies/patient-public-partnership/ [Accessed 11 Sept 2023] 

  157. Husson M, Dechartres A, Ramdjee B, et al. Patient and public involvement is suboptimal in randomized controlled trials addressing a chronic condition. J Clin Epidemiol 2023;160:71-82. PubMed doi:10.1016/j.jclinepi.2023.06.012

  158. de Iongh A, Severwright A, Taylor J. Patient and public involvement statements in British journal of occupational therapy: An important step. Br J Occup Ther 2021;84:459-60 doi:10.1177/03080226211030103.

  159. Research Involvement and Engagement: preparing your manuscript. https://researchinvolvement.biomedcentral.com/submission-guidelines/preparing-your-manuscript/research [Accessed 2023-10-19]

  160. Davis S, Pinfold V, Catchpole J, Lovelock C, Senthi B, Kenny A. Reporting lived experience work. Lancet Psychiatry 2024;11:8-9. PubMed doi:10.1016/S2215-0366(23)00402-9

  161. Gray R, Brasier C, Zirnsak T-M, Ng AH. Reporting of patient and public involvement and engagement (PPIE) in clinical trials published in nursing science journals: a descriptive study. Res Involv Engagem 2021;7:88. PubMed doi:10.1186/s40900-021-00331-9

  162. Patel VA, Shelswell J, Hillyard N, Pavitt S, Barber SK. A study of the reporting of patient and public involvement and engagement (PPIE) in orthodontic research. J Orthod 2021;48:42-51. PubMed doi:10.1177/1465312520968574

  163. Benizri N, Hallot S, Burns K, Goldfarb M. Patient and family representation in randomized clinical trials published in 3 medical and surgical journals: a systematic review. JAMA Netw Open 2022;5:e2230858. PubMed doi:10.1001/jamanetworkopen.2022.30858

  164. Vanderhout S, Nevins P, Nicholls SG, et al. Patient and public involvement in pragmatic trials: online survey of corresponding authors of published trials. CMAJ Open 2023;11:E826-37. PubMed doi:10.9778/cmajo.20220198

  165. Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age. Pediatrics 2009;123:e770-6. PubMed doi:10.1542/peds.2008-2945

  166. Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement. JAMA 2019;321:1610-20. PubMed doi:10.1001/jama.2019.3087

  167. Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ 2019;366:l4378. PubMed doi:10.1136/bmj.l4378

  168. Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ 2012;345:e5661. PubMed doi:10.1136/bmj.e5661

  169. Odutayo A, Emdin CA, Hsiao AJ, et al. Association between trial registration and positive study findings: cross sectional study (Epidemiological Study of Randomized Trials-ESORT). BMJ 2017;356:j917. PubMed doi:10.1136/bmj.j917

  170. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90. PubMed doi:10.1016/S0140-6736(00)04560-8

  171. Santer M, Muller I, Becque T, et al. Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials. BMJ 2022;379:e072007. PubMed doi:10.1136/bmj-2022-072007

  172. Orkin AM, Gill PJ, Ghersi D, et al; CONSERVE Group. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. JAMA 2021;326:257-65. PubMed doi:10.1001/jama.2021.9941

  173. Grant AM, Altman DG, Babiker AB, et al; DAMOCLES study group. Issues in data monitoring and interim analysis of trials. Health Technol Assess 2005;9:1-238, iii-iv. PubMed doi:10.3310/hta9070

  174. Dimairo M, Pallmann P, Wason J, et al; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ 2020;369:m115. PubMed doi:10.1136/bmj.m115

  175. Chan AW, Krleza-Jerić K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004;171:735-40. PubMed doi:10.1503/cmaj.1041086

  176. TARG Meta-Research Group & Collaborators. Estimating the prevalence of discrepancies between study registrations and publications: a systematic review and meta-analyses. BMJ Open 2023;13:e076264. PubMed doi:10.1136/bmjopen-2023-076264

  177. Blair JC, McKay A, Ridyard C, et al; SCIPI investigators. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation. BMJ 2019;365:l1226. PubMed doi:10.1136/bmj.l1226

  178. Tappin D, Bauld L, Purves D, et al; Cessation in Pregnancy Incentives Trial Team. Financial incentives for smoking cessation in pregnancy: randomised controlled trial. BMJ 2015;350:h134. PubMed doi:10.1136/bmj.h134

  179. Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 2005;365:82-93. PubMed doi:10.1016/S0140-6736(04)17670-8

  180. Weiss NS, Koepsell TD, Psaty BM. Generalizability of the results of randomized trials. Arch Intern Med 2008;168:133-5. PubMed doi:10.1001/archinternmed.2007.30

  181. Hopewell S, Keene DJ, Marian IR, et al; GRASP Trial Group. Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial. Lancet 2021;398:416-28. PubMed doi:10.1016/S0140-6736(21)00846-1

  182. Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev 2016;1:2. PubMed doi:10.1186/s41073-016-0007-6

  183. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007;297:1233-40. PubMed doi:10.1001/jama.297.11.1233

  184. Blümle A, Meerpohl JJ, Rücker G, Antes G, Schumacher M, von Elm E. Reporting of eligibility criteria of randomised trials: cohort study comparing trial protocols with subsequent articles. BMJ 2011;342:d1828. PubMed doi:10.1136/bmj.d1828

  185. Shapiro SH, Weijer C, Freedman B. Reporting the study populations of clinical trials. Clear transmission or static on the line? J Clin Epidemiol 2000;53:973-9. PubMed doi:10.1016/S0895-4356(00)00227-4

  186. Gandhi M, Ameli N, Bacchetti P, et al. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS 2005;19:1885-96. PubMed doi:10.1097/01.aids.0000189866.67182.f7

  187. Molyneux A, Kerr R, Stratton I, et al; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002;360:1267-74. PubMed doi:10.1016/S0140-6736(02)11314-6

  188. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P; CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008;148:295-309. PubMed doi:10.7326/0003-4819-148-4-200802190-00008

  189. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med 2002;137:511-20. PubMed doi:10.7326/0003-4819-137-6-200209170-00012

  190. Devereaux PJ, Bhandari M, Clarke M, et al. Need for expertise based randomised controlled trials. BMJ 2005;330:88. PubMed doi:10.1136/bmj.330.7482.88

  191. McGrath PD, Wennberg DE, Dickens JD Jr, et al. Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent. JAMA 2000;284:3139-44. PubMed doi:10.1001/jama.284.24.3139

  192. Hodgson DC, Zhang W, Zaslavsky AM, Fuchs CS, Wright WE, Ayanian JZ. Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst 2003;95:708-16. PubMed doi:10.1093/jnci/95.10.708

  193. Khuri SF, Daley J, Henderson W, et al. Relation of surgical volume to outcome in eight common operations: results from the VA National Surgical Quality Improvement Program. Ann Surg 1999;230:414-29, discussion 429-32. PubMed doi:10.1097/00000658-199909000-00014

  194. Urbach DR, Baxter NN. Does it matter what a hospital is “high volume” for? Specificity of hospital volume-outcome associations for surgical procedures: analysis of administrative data. Qual Saf Health Care 2004;13:379-83. PubMed doi:10.1136/qhc.13.5.379

  195. Jacquier I, Boutron I, Moher D, Roy C, Ravaud P. The reporting of randomized clinical trials using a surgical intervention is in need of immediate improvement: a systematic review. Ann Surg 2006;244:677-83. PubMed doi:10.1097/01.sla.0000242707.44007.80

  196. Madanitsa M, Barsosio HC, Minja DTR, et al. Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial. Lancet 2023;401:1020-36. PubMed doi:10.1016/S0140-6736(22)02535-1

  197. Nguyen C, Boutron I, Zegarra-Parodi R, et al. Effect of osteopathic manipulative treatment vs sham treatment on activity limitations in patients with nonspecific subacute and chronic low back pain: a randomized clinical trial. JAMA Intern Med 2021;181:620-30. PubMed doi:10.1001/jamainternmed.2021.0005

  198. Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from descriptions of treatment in trials and reviews? BMJ 2008;336:1472-4. PubMed doi:10.1136/bmj.39590.732037.47

  199. Duff JM, Leather H, Walden EO, LaPlant KD, George TJ Jr. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 2010;102:702-5. PubMed doi:10.1093/jnci/djq117

  200. Schroter S, Glasziou P, Heneghan C. Quality of descriptions of treatments: a review of published randomised controlled trials. BMJ Open 2012;2:e001978. PubMed doi:10.1136/bmjopen-2012-001978

  201. Hoffmann TC, Erueti C, Glasziou PP. Poor description of non-pharmacological interventions: analysis of consecutive sample of randomised trials. BMJ 2013;347:f3755. PubMed doi:10.1136/bmj.f3755

  202. Abell B, Glasziou P, Hoffmann T. Reporting and replicating trials of exercise-based cardiac rehabilitation: do we know what the researchers actually did? Circ Cardiovasc Qual Outcomes 2015;8:187-94. PubMed doi:10.1161/CIRCOUTCOMES.114.001381

  203. Ndounga Diakou LA, Ntoumi F, Ravaud P, Boutron I. Avoidable waste related to inadequate methods and incomplete reporting of interventions: a systematic review of randomized trials performed in Sub-Saharan Africa. Trials 2017;18:291. PubMed doi:10.1186/s13063-017-2034-0

  204. Golomb BA, Erickson LC, Koperski S, Sack D, Enkin M, Howick J. What’s in placebos: who knows? Analysis of randomized, controlled trials. Ann Intern Med 2010;153:532-5. PubMed doi:10.7326/0003-4819-153-8-201010190-00010

  205. Yu AM, Balasubramanaiam B, Offringa M, Kelly LE. Reporting of interventions and “standard of care” control arms in pediatric clinical trials: a quantitative analysis. Pediatr Res 2018;84:393-8. PubMed doi:10.1038/s41390-018-0019-7

  206. Sanders S, Gibson E, Glasziou P, Hoffmann T. Nondrug interventions for reducing SARS-CoV-2 transmission are frequently incompletely reported. J Clin Epidemiol 2023;157:102-9. PubMed doi:10.1016/j.jclinepi.2023.02.006

  207. Howick J, Webster RK, Rees JL, et al. TIDieR-Placebo: A guide and checklist for reporting placebo and sham controls. PLoS Med 2020;17:e1003294. PubMed doi:10.1371/journal.pmed.1003294

  208. Phillips WR, Sturgiss E, Hunik L, et al. Improving the Reporting of Primary Care Research: An International Survey of Researchers. J Am Board Fam Med 2021;34:12-21. PubMed doi:10.3122/jabfm.2021.01.200266

  209. Dodd S, White IR, Williamson P. Nonadherence to treatment protocol in published randomised controlled trials: a review. Trials 2012;13:84. PubMed doi:10.1186/1745-6215-13-84

  210. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. PubMed doi:10.1136/bmj.l4898

  211. Higgins J, Sterne J, Savović J, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V, eds. Cochrane Methods Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1). 2016: 29-32

  212. Zuidgeest MGP, Welsing PMJ, van Thiel GJMW, et al; WP3 of the GetReal consortium. Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators. J Clin Epidemiol 2017;90:92-8. PubMed doi:10.1016/j.jclinepi.2017.07.001

  213. Turner KM, Huntley A, Yardley T, Dawson S, Dawson S. Defining usual care comparators when designing pragmatic trials of complex health interventions: a methodology review. Trials 2024;25:117. PubMed doi:10.1186/s13063-024-07956-7

  214. Webster RK, Howick J, Hoffmann T, et al. Inadequate description of placebo and sham controls in a systematic review of recent trials. Eur J Clin Invest 2019;49:e13169. PubMed doi:10.1111/eci.13169

  215. Paterson C, Dieppe P. Characteristic and incidental (placebo) effects in complex interventions such as acupuncture. BMJ 2005;330:1202-5. PubMed doi:10.1136/bmj.330.7501.1202

  216. Bannuru RR, McAlindon TE, Sullivan MC, Wong JB, Kent DM, Schmid CH. Effectiveness and Implications of Alternative Placebo Treatments: A Systematic Review and Network Meta-analysis of Osteoarthritis Trials. Ann Intern Med 2015;163:365-72. PubMed doi:10.7326/M15-0623

  217. COMET. Core Outcome Measures in Effectiveness Trials.             https://comet-initiative.org/ [Accessed 6 Nov 2023]

  218. Hughes KL, Clarke M, Williamson PR. A systematic review finds Core Outcome Set uptake varies widely across different areas of health. J Clin Epidemiol 2021;129:114-23. PubMed doi:10.1016/j.jclinepi.2020.09.029

  219. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database--update and key issues. N Engl J Med 2011;364:852-60. PubMed doi:10.1056/NEJMsa1012065

  220. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005;365:1159-62. PubMed doi:10.1016/S0140-6736(05)71879-1

  221. Hopewell S, Dutton S, Yu L-M, Chan A-W, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010;340:c723. PubMed doi:10.1136/bmj.c723

  222. Bridgman AC, McPhie ML, Voineskos SH, Chan A-W, Drucker AM. Reporting of primary outcome measures and sample size calculations in randomized controlled trials in dermatology journals. J Am Acad Dermatol 2022;87:912-4. PubMed doi:10.1016/j.jaad.2021.12.022

  223. Stoll M, Lindner S, Marquardt B, et al. Completeness and consistency of primary outcome reporting in COVID-19 publications in the early pandemic phase: a descriptive study. BMC Med Res Methodol 2023;23:173. PubMed doi:10.1186/s12874-023-01991-9

  224. McDowell I. Measuring health: a guide to rating scales and questionnaires. 3rd ed. Oxford University Press, 2006 doi:10.1093/acprof:oso/9780195165678.001.0001.

  225. Streiner DL, Norman GR, Cairney J. Health measurement scales: a practical guide to their development and use: Oxford University Press; 2015

  226. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998;317:1191-4. PubMed doi:10.1136/bmj.317.7167.1191

  227. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials 2007;8:39. PubMed doi:10.1186/1745-6215-8-39

  228. Mc Cord KA, Ewald H, Agarwal A, et al. Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study. BMJ 2021;372:n450. PubMed doi:10.1136/bmj.n450

  229. Torre-Cisneros J, San-Juan R, Rosso-Fernández CM, et al. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis 2015;60:1642-9. PubMed doi:10.1093/cid/civ156

  230. Mohraz M, Vahdat K, Ghamari SH, et al. Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. BMJ 2023;382:e070464. PubMed doi:10.1136/bmj-2023-070464

  231. Qureshi R, Mayo-Wilson E, Li T. Harms in Systematic Reviews Paper 1: An introduction to research on harms. J Clin Epidemiol 2022;143:186-96. PubMed doi:10.1016/j.jclinepi.2021.10.023

  232. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-68. PubMed doi:10.1001/jama.2013.278040

  233. Mayo-Wilson E, Fusco N, Li T, Hong H, Canner JK, Dickersin K; MUDS investigators. Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. J Clin Epidemiol 2019;113:11-9. PubMed doi:10.1016/j.jclinepi.2019.04.020

  234. Bagul NB, Kirkham JJ. The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting. Clin Exp Hypertens 2012;34:548-54. PubMed doi:10.3109/10641963.2012.681724

  235. Qureshi R, Mayo-Wilson E, Rittiphairoj T, McAdams-DeMarco M, Guallar E, Li T. Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin. J Clin Epidemiol 2022;143:212-23. PubMed doi:10.1016/j.jclinepi.2021.10.024

  236. Qureshi R, Mayo-Wilson E, Rittiphairoj T, McAdams-DeMarco M, Guallar E, Li T. Harms in Systematic Reviews Paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms. J Clin Epidemiol 2022;143:224-41. PubMed doi:10.1016/j.jclinepi.2021.10.025

  237. Stephens MDB, Routledge P, Talbot JCC. Detection of new adverse drug reactions. 4th ed. Macmillan Basingstoke, 1998.

  238. Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM. Streamlining adverse events reporting in oncology: an american society of clinical oncology research statement. J Clin Oncol 2018;36:617-23. PubMed doi:10.1200/JCO.2017.75.8193

  239. Taïeb J, Bouche O, André T, et al; SAMCO-PRODIGE 54 Investigators. Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: a randomized clinical trial. JAMA Oncol 2023;9:1356-63. PubMed doi:10.1001/jamaoncol.2023.2761

  240. Casswell EJ, Cro S, Cornelius VR, et al; ASCOT Investigator Study Group. Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study. Br J Ophthalmol 2024;108:440-8. PubMed doi:10.1136/bjo-2022-322787

  241. Khunti K, Highton PJ, Waheed G, et al. Promoting physical activity with self-management support for those with multimorbidity: a randomised controlled trial. Br J Gen Pract 2021;71:e921-30. PubMed doi:10.3399/BJGP.2021.0172

  242. Palmer AJR, Ayyar Gupta V, Fernquest S, et al; FAIT Study Group. Arthroscopic hip surgery compared with physiotherapy and activity modification for the treatment of symptomatic femoroacetabular impingement: multicentre randomised controlled trial. BMJ 2019;364:l185. PubMed doi:10.1136/bmj.l185

  243. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 1995;311:1145-8. PubMed doi:10.1136/bmj.311.7013.1145

  244. Cook JA, Julious SA, Sones W, et al. DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. BMJ 2018;363:k3750. PubMed doi:10.1136/bmj.k3750

  245. Pandis N, Chung B, Scherer RW, Elbourne D, Altman DG. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ 2017;357:j2835. PubMed doi:10.1136/bmj.j2835

  246. Speich B. Adequate reporting of the sample size calculation in surgical randomized controlled trials. Surgery 2020;167:812-4. PubMed doi:10.1016/j.surg.2019.10.011

  247. Weinberg T, Wang G, Lam K, Kitchen J, Chan A-W. Reporting of sample-size calculations for randomized trials in dermatology: comparison of publications with registries. Br J Dermatol 2019;180:929-30. PubMed doi:10.1111/bjd.17332

  248. Amiri M, Kumbhare D. Randomized controlled trials in non-pharmacological rehabilitation research: a scoping review of the reporting of sample size calculation, randomization procedure, and statistical analyses. Eur J Phys Rehabil Med 2020;56:790-8. PubMed

  249. Dumbrigue HB, Dumbrigue EC, Dumbrigue DC, Chingbingyong MI. Reporting of sample size parameters in randomized controlled trials published in prosthodontic journals. J Prosthodont 2019;28:159-62. PubMed doi:10.1111/jopr.13010

  250. Nontshe M, Khan S, Mandebvu T, Merrifield B, Rodseth RN. Sample-size determination and adherence in randomised controlled trials published in anaesthetic journals. Southern Afr J Anaesth Analg 2018;24:40-6 doi:10.1080/22201181.2018.1439602 .

  251. Copsey B, Thompson JY, Vadher K, et al. Sample size calculations are poorly conducted and reported in many randomized trials of hip and knee osteoarthritis: results of a systematic review. J Clin Epidemiol 2018;104:52-61. PubMed doi:10.1016/j.jclinepi.2018.08.013

  252. Lee PH, Tse ACY. The quality of the reported sample size calculations in randomized controlled trials indexed in PubMed. Eur J Intern Med 2017;40:16-21. PubMed doi:10.1016/j.ejim.2016.10.008

  253. Althouse AD. Post hoc power: not empowering, just misleading. J Surg Res 2021;259:A3-6. PubMed doi:10.1016/j.jss.2019.10.049

  254. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994;121:200-6. PubMed doi:10.7326/0003-4819-121-3-199408010-00008

  255. Horne AW, Tong S, Moakes CA, et al; GEM3 collaborative. Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2023;401:655-63. PubMed doi:10.1016/S0140-6736(22)02478-3

  256. Hall DA, Ray J, Watson J, et al. A balanced randomised placebo controlled blinded phase IIa multi-centre study to investigate the efficacy and safety of AUT00063 versus placebo in subjective tinnitus: The QUIET-1 trial. Hear Res 2019;377:153-66. PubMed doi:10.1016/j.heares.2019.03.018

  257. Hogan LE, Brown PA, Ji L, et al. Children’s Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse. J Clin Oncol 2023;41:4118-29. PubMed doi:10.1200/JCO.22.02200

  258. Reignier J, Plantefeve G, Mira JP, et al; NUTRIREA-3 Trial Investigators; Clinical Research in Intensive Care; Sepsis (CRICS-TRIGGERSEP)Group. Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3). Lancet Respir Med 2023;11:602-12. PubMed doi:10.1016/S2213-2600(23)00092-9

  259. Ciolino JD, Kaizer AM, Bonner LB. Guidance on interim analysis methods in clinical trials. J Clin Transl Sci 2023;7:e124. PubMed doi:10.1017/cts.2023.552

  260. Stegert M, Kasenda B, von Elm E, et al; DISCO study group. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. J Clin Epidemiol 2016;69:152-60. PubMed doi:10.1016/j.jclinepi.2015.05.023

  261. Padoei F, Mamsharifi P, Hazegh P, et al. The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial. Brain Behav 2023;13:e2823. PubMed doi:10.1002/brb3.2823

  262. Karyotaki E, Klein AM, Ciharova M, et al. Guided internet-based transdiagnostic individually tailored Cognitive Behavioral Therapy for symptoms of depression and/or anxiety in college students: A randomized controlled trial. Behav Res Ther 2022;150:104028. PubMed doi:10.1016/j.brat.2021.104028

  263. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ 1948;2:769-82. PubMed doi:10.1136/bmj.2.4582.769

  264. Schulz KF. Randomized controlled trials. Clin Obstet Gynecol 1998;41:245-56. PubMed doi:10.1097/00003081-199806000-00005

  265. Greenland S. Randomization, statistics, and causal inference. Epidemiology 1990;1:421-9. PubMed doi:10.1097/00001648-199011000-00003

​266. Armitage P. The role of randomization in clinical trials. Stat Med 1982;1:345-52. PubMed doi:10.1002/sim.4780010412

267. Kleijnen J, Gøtzsche P, Kunz RA, Oxman A, Chalmers I. So what’s so special about randomisation? In: Manynard A, Chalmers I, eds. Non-

random reflections on health services research. BMJ Publishing Group, 1997: 93-106

268. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates   

of treatment effects in controlled trials. JAMA 1995;273:408-12. PubMed doi:10.1001/jama.1995.03520290060030

269. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in             

obstetrics and gynecology journals. JAMA 1994;272:125-8. PubMed doi:10.1001/jama.1994.03520020051014

270. Chalmers I. Assembling comparison groups to assess the effects of health care. J R Soc Med 1997;90:379-86.

PubMeddoi:10.1177/014107689709000706

271. Altman DG. Randomisation. BMJ 1991;302:1481-2. PubMed doi:10.1136/bmj.302.6791.1481

272. Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of

Reporting Trials. JAMA 1998;279:1489-91. PubMed doi:10.1001/jama.279.18.1489

273. Kjaergard L, Villumsen J, Gluud C. Quality of randomised clinical trials affects estimates of intervention efficacy. The best evidence for         

health care: the role of The Cochrane Collaboration - abstracts of the 7th Cochrane Colloquium; 1999 5-9 Oct; Rome, Italy 1999.

274. Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. In: Egger M, Davey Smith G, Altman DG, eds. Systematic           

Reviews in Health Care: Meta-analysis in Context. BMJ Books, 2001 doi:10.1002/9780470693926.ch5.

275. Savović J, Jones H, Altman D, et al. Influence of reported study design characteristics on intervention effect estimates from randomised     

controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 2012;16:1-82. PubMed doi:10.3310/hta16350

276. Savović J, Turner RM, Mawdsley D, et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane

reviews: the ROBES meta-epidemiologic study. Am J Epidemiol 2018;187:1113-22. PubMed doi:10.1093/aje/kwx344

277. Saltaji H, Armijo-Olivo S, Cummings GG, Amin M, da Costa BR, Flores-Mir C. Impact of selection bias on treatment effect size estimates in

randomized trials of oral health interventions: a meta-epidemiological study. J Dent Res 2018;97:5-13. PubMed doi:10.1177/0022034517725049

278. Armijo-Olivo S, Saltaji H, da Costa BR, Fuentes J, Ha C, Cummings GG. What is the influence of randomisation sequence generation and

allocation concealment on treatment effects of physical therapy trials? A meta-epidemiological study. BMJ Open 2015;5:e008562. PubMed doi:10.1136/bmjopen-2015-008562

279. Barcot O, Boric M, Poklepovic Pericic T, et al. Risk of bias judgments for random sequence generation in Cochrane systematic reviews

were frequently not in line with Cochrane Handbook. BMC Med Res Methodol 2019;19:170. PubMed doi:10.1186/s12874-019-0804-y

280. Mentz RJ, Anstrom KJ, Eisenstein EL, et al; TRANSFORM-HF Investigators. Effect of torsemide vs furosemide after discharge on all-cause

mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA 2023;329:214-23. PubMed doi:10.1001/jama.2022.23924

281. Statema-Lohmeijer CH, Schats R, Lissenberg-Witte BI, Kostelijk EH, Lambalk CB, Vergouw CG. A short versus a long time interval between

semen collection and intrauterine insemination: a randomized controlled clinical trial. Hum Reprod 2023;38:811-9. PubMed doi:10.1093/humrep/dead044

282. Reichenbach S, Jüni P, Hincapié CA, et al. Effect of transcutaneous electrical nerve stimulation (TENS) on knee pain and physical function

in patients with symptomatic knee osteoarthritis: the ETRELKA randomized clinical trial. Osteoarthritis Cartilage 2022;30:426-35. PubMed doi:10.1016/j.joca.2021.10.015

283. Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet

Gynecol 2008;111:267-77. PubMed doi:10.1097/01.AOG.0000298338.58511.d1

284. Lachin JM. Properties of simple randomization in clinical trials. Control Clin Trials 1988;9:312-26.

PubMed doi:10.1016/0197-2456(88)90046-3

285. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I.

Introduction and design. Br J Cancer 1976;34:585-612. PubMed doi:10.1038/bjc.1976.220

286. Schulz K, Grimes DA. Essential concepts in clinical research: randomized controlled trials and observational epidemiology. 2nd ed.

Elsevier, 2019.

287. Altman DG, Bland JM. Statistics notes: how to randomise. BMJ 1999;319:703-4. PubMed doi:10.1136/bmj.319.7211.703

288. Schulz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456-8. PubMed doi:10.1001/jama.1995.03530180050029

289. Enas GG, Enas NH, Spradlin CT, Wilson MG, Wiltse CG. Baseline comparability in clinical trials: prevention of “poststudy anxiety”. Drug Inf J

1990;24:541-8 doi:10.1177/009286159002400312.

290. Pocock SJ. Clinical trials: a practical approach. John Wiley & Sons Ltd, 1983.

291. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn’t guarantee similarity of groups;

minimisation does. BMJ 1998;317:362-3. PubMed doi:10.1136/bmj.317.7155.362

292. Kahan BC, Rehal S, Cro S. Risk of selection bias in randomised trials. Trials 2015;16:405. PubMed doi:10.1186/s13063-015-0920-x

293. Clark L, Burke L, Margaret Carr R, Coleman E, Roberts G, Torgerson DJ. A review found small variable blocking schemes may not protect

against selection bias in randomized controlled trials. J Clin Epidemiol 2022;141:90-8. PubMed doi:10.1016/j.jclinepi.2021.09.009

294. Altman DG, Doré CJ. Randomisation and baseline comparisons in clinical trials. Lancet 1990;335:149-53.

PubMed doi:10.1016/0140-6736(90)90014-V

295. Adetugbo K, Williams H. How well are randomized controlled trials reported in the dermatology literature? Arch Dermatol 2000;136:381-

5. PubMed doi:10.1001/archderm.136.3.381

296. Ciolino JD, Palac HL, Yang A, Vaca M, Belli HM. Ideal vs. real: a systematic review on handling covariates in randomized controlled trials.

BMC Med Res Methodol 2019;19:136. PubMed doi:10.1186/s12874-019-0787-8

297. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two

randomised, double-blind, placebo-controlled, phase 3 studies. Lancet 2023;401:1159-71. PubMed doi:10.1016/S0140-6736(23)00061-2

298. Rai AV, Naik BD. Evaluation of remineralizing effect of zinc-carbonate hydroxyapatite on the reduction of postrestorative sensitivity: A

randomized controlled clinical trial. J Conserv Dent 2023;26:56-66. PubMed doi:10.4103/jcd.jcd_300_22

299. Mendon A FÍT, Barreto Filho JH, Hungria MBCS, Magalh Es TC. Efficacy of a single dose of esmolol to prevent extubation-related

complications during emergence from anesthesia: a randomized, double-blind, placebo-controlled trial. Braz J Anesthesiol 2023;73:426-33. PubMed

300. Rattanathanya T, Adulkasem N, Wongcharoenwatana J, Ariyawatkul T, Chotigavanichaya C, Eamsobhana P. Perioperative blood loss

reduction using a sterile exsanguination tourniquet for orthopedic femoral-related surgeries in children: a randomized controlled study. J Orthop Surg Res 2023;18:580. PubMed doi:10.1186/s13018-023-04046-3

301. Radford JA, Landorf KB, Buchbinder R, Cook C. Effectiveness of low-Dye taping for the short-term treatment of plantar heel pain: a

randomised trial. BMC Musculoskelet Disord 2006;7:64. PubMed doi:10.1186/1471-2474-7-64

302. Chalmers TC, Levin H, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline. I: Control of

bias and comparison with large co-operative trials. Stat Med 1987;6:315-28. PubMed doi:10.1002/sim.4780060320

303. Pocock SJ. Statistical aspects of clinical trial design. Statistician 2018;31:1-18 doi:10.2307/2988097.

304. Piaggio G, Elbourne D, Schulz KF, Villar J, Pinol AP, Gülmezoglu AM; WHO Research Group to evaluate Misoprostol in the Management of

the Third Stage of Labour. The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial. BMC Med Res Methodol 2003;3:19. PubMed doi:10.1186/1471-2288-3-19

305. Clark L, Mitchell N, Hewitt C, Torgerson D. Exploring engagement with authors of randomised controlled trials to develop

recommendations to improve allocation concealment implementation and reporting. F1000 Res 2021;10:83 doi:10.12688/f1000research.27918.1.

306. Clark L, Schmidt U, Tharmanathan P, Adamson J, Hewitt C, Torgerson D. Poor reporting quality of key Randomization and Allocation

Concealment details is still prevalent among published RCTs in 2011: a review. J Eval Clin Pract 2013;19:703-7. PubMed doi:10.1111/jep.12031

307. Pildal J, Hróbjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from

meta-analyses of randomized trials. Int J Epidemiol 2007;36:847-57. PubMed doi:10.1093/ije/dym087

308. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions

and outcomes: meta-epidemiological study. BMJ 2008;336:601-5. PubMed doi:10.1136/bmj.39465.451748.AD

309. Wang Y, Parpia S, Couban R, et al. Compelling evidence from meta-epidemiological studies demonstrates overestimation of effects in

randomized trials that fail to optimize randomization and blind patients and outcome assessors. J Clin Epidemiol 2024;165:111211. PubMed doi:10.1016/j.jclinepi.2023.11.001

310. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in

rheumatoid arthritis. Control Clin Trials 1989;10:31-56. PubMed doi:10.1016/0197-2456(89)90017-2

311. Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A. Published methodological quality of randomized controlled trials does not

reflect the actual quality assessed in protocols. J Clin Epidemiol 2012;65:602-9. PubMed doi:10.1016/j.jclinepi.2011.10.016

312. Clark L, Schmidt U, Tharmanathan P, Adamson J, Hewitt C, Torgerson D. Allocation concealment: a methodological review. J Eval Clin Pract

2013;19:708-12. PubMed doi:10.1111/jep.12032

313. He J, Du L, Liu G, et al. Quality assessment of reporting of randomization, allocation concealment, and blinding in traditional Chinese medicine

RCTs: a review of 3159 RCTs identified from 260 systematic reviews. Trials 2011;12:122. PubMed doi:10.1186/1745-6215-12-122

314. Zheng SL, Chan FT, Maclean E, Jayakumar S, Nabeebaccus AA. Reporting trends of randomised controlled trials in heart failure with

preserved ejection fraction: a systematic review. Open Heart 2016;3:e000449. PubMed doi:10.1136/openhrt-2016-000449

315. Kilicoglu H, Jiang L, Hoang L, Mayo-Wilson E, Vinkers CH, Otte WM. Methodology reporting improved over time in 176,469 randomized

controlled trials. J Clin Epidemiol 2023;162:19-28. PubMed doi:10.1016/j.jclinepi.2023.08.004

316. Binks MJ, Bleakley AS, Pizzutto SJ, et al. Randomised controlled trial of perinatal vitamin D supplementation to prevent early-onset acute

respiratory infections among Australian First Nations children: the ‘D-Kids’ study protocol. BMJ Open Respir Res 2023;10:e001646. PubMed doi:10.1136/bmjresp-2023-001646

317. Jones CMP, Day RO, Koes BW, et al; OPAL Investigators Coordinators. Opioid analgesia for acute low back pain and neck pain (the OPAL

trial): a randomised placebo-controlled trial. Lancet 2023;402:304-12. PubMed doi:10.1016/S0140-6736(23)00404-X

318. Evans JT, Stanesby O, Blizzard L, et al. trips4health: a single-blinded randomised controlled trial incentivising adult public transport use for

physical activity gain. Int J Behav Nutr Phys Act 2023;20:98. PubMed doi:10.1186/s12966-023-01500-7

319. Webster J, Clarke S, Paterson D, et al. Routine care of peripheral intravenous catheters versus clinically indicated replacement:

randomised controlled trial. BMJ 2008;337:a339. PubMed doi:10.1136/bmj.a339

320. Smith SA, Shah ND, Bryant SC, et al; Evidens Research Group. Chronic care model and shared care in diabetes: randomized trial of an

electronic decision support system. Mayo Clin Proc 2008;83:747-57. PubMed doi:10.4065/83.7.747

321. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J

Med 2009;360:859-73. PubMed doi:10.1056/NEJMoa0804748

322. Kaptchuk TJ. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull Hist Med 1998;72:389-433.

PubMed doi:10.1353/bhm.1998.0159

323. Devereaux PJ, Manns BJ, Ghali WA, et al. Physician interpretations and textbook definitions of blinding terminology in randomized

controlled trials. JAMA 2001;285:2000-3. PubMed doi:10.1001/jama.285.15.2000

324. Haahr MT, Hróbjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials

2006;3:360-5. PubMed doi:10.1177/1740774506069153

325. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials 1996;17:285-90, discussion 290-3.

PubMed doi:10.1016/0197-2456(95)00263-4

326. Meinert CL. Masked monitoring in clinical trials--blind stupidity? N Engl J Med 1998;338:1381-2.

PubMed doi:10.1056/NEJM199805073381911

327. Guyatt GH, Pugsley SO, Sullivan MJ, et al. Effect of encouragement on walking test performance. Thorax 1984;39:818-22.

PubMed doi:10.1136/thx.39.11.818

328. Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. Ascorbic acid for the common cold. A prophylactic and

therapeutic trial. JAMA 1975;231:1038-42. PubMed doi:10.1001/jama.1975.03240220018013

329. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized,

placebo-controlled multiple sclerosis clinical trial. Neurology 1994;44:16-20. PubMed doi:10.1212/WNL.44.1.16

330. Janiaud P, Dal-Ré R, Ioannidis JPA. Assessment of Pragmatism in Recently Published Randomized Clinical Trials. JAMA Intern Med

2018;178:1278-80. PubMed doi:10.1001/jamainternmed.2018.3321

331. Carley SD, Libetta C, Flavin B, Butler J, Tong N, Sammy I. An open prospective randomised trial to reduce the pain of blood glucose testing:

ear versus thumb. BMJ 2000;321:20. PubMed doi:10.1136/bmj.321.7252.20

332. Martin GL, Trioux T, Gaudry S, Tubach F, Hajage D, Dechartres A. Association between lack of blinding and mortality results in critical care

randomized controlled trials: a meta-epidemiological study. Crit Care Med 2021;49:1800-11. PubMed doi:10.1097/CCM.0000000000005065

333. Hróbjartsson A, Thomsen ASS, Emanuelsson F, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review

of trials with both blinded and non-blinded outcome assessors. BMJ 2012;344:e1119. PubMed doi:10.1136/bmj.e1119

334. Hróbjartsson A, Thomsen ASS, Emanuelsson F, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a

systematic review of trials with both blinded and nonblinded assessors. CMAJ 2013;185:E201-11. PubMed doi:10.1503/cmaj.120744

335. Hróbjartsson A, Thomsen ASS, Emanuelsson F, et al. Observer bias in randomized clinical trials with time-to-event outcomes: systematic

review of trials with both blinded and non-blinded outcome assessors. Int J Epidemiol 2014;43:937-48. PubMed doi:10.1093/ije/dyt270

336. Hróbjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S. Bias due to lack of patient blinding in clinical trials. A systematic

review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol 2014;43:1272-83. PubMed doi:10.1093/ije/dyu115

337. Bialy L, Vandermeer B, Lacaze-Masmonteil T, Dryden DM, Hartling L. A meta-epidemiological study to examine the association between

bias and treatment effects in neonatal trials. Evid Based Child Health 2014;9:1052-9. PubMed doi:10.1002/ebch.1985

338. Armijo-Olivo S, Fuentes J, da Costa BR, Saltaji H, Ha C, Cummings GG. Blinding in physical therapy trials and its association with treatment

effects: a meta-epidemiological study. Am J Phys Med Rehabil 2017;96:34-44. PubMed doi:10.1097/PHM.0000000000000521

339. Armijo-Olivo S, Dennett L, Arienti C, et al. Blinding in rehabilitation research: empirical evidence on the association between blinding and

treatment effect estimates. Am J Phys Med Rehabil 2020;99:198-209. PubMed doi:10.1097/PHM.0000000000001377

340. Zeraatkar D, Pitre T, Diaz-Martinez JP, et al. Impact of allocation concealment and blinding in trials addressing treatments for COVID-19: a

methods study. Am J Epidemiol 2023;192:1678-87. PubMed doi:10.1093/aje/kwad131

341. Moustgaard H, Clayton GL, Jones HE, et al. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-

epidemiological study. BMJ 2020;368:l6802. PubMed doi:10.1136/bmj.l6802

342. Mouillet G, Efficace F, Thiery-Vuillemin A, et al. Investigating the impact of open label design on patient-reported outcome results in

prostate cancer randomized controlled trials. Cancer Med 2020;9:7363-74. PubMed doi:10.1002/cam4.3335

343. Anthon CT, Granholm A, Perner A, Laake JH, Møller MH. No firm evidence that lack of blinding affects estimates of mortality in

randomized clinical trials of intensive care interventions: a systematic review and meta-analysis. J Clin Epidemiol 2018;100:71-81. PubMed doi:10.1016/j.jclinepi.2018.04.016

344. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med 2002;136:254-9.

PubMed doi:10.7326/0003-4819-136-3-200202050-00022

345. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ 2000;321:504. PubMed doi:10.1136/bmj.321.7259.504

346. Boutron I, Estellat C, Guittet L, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a

systematic review. PLoS Med 2006;3:e425. PubMed doi:10.1371/journal.pmed.0030425

347. Boutron I, Guittet L, Estellat C, Moher D, Hróbjartsson A, Ravaud P. Reporting methods of blinding in randomized trials assessing

nonpharmacological treatments. PLoS Med 2007;4:e61. PubMed doi:10.1371/journal.pmed.0040061

348. Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In the dark: the reporting of blinding status in randomized

controlled trials. J Clin Epidemiol 2002;55:787-90. PubMed doi:10.1016/S0895-4356(02)00446-8

349. Dechartres A, Trinquart L, Atal I, et al. Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled

trials included in Cochrane reviews: research on research study. BMJ 2017;357:j2490. PubMed doi:10.1136/bmj.j2490

350. Cheng K, Smyth RL, Motley J, O’Hea U, Ashby D. Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design,

and intervention. Pediatr Pulmonol 2000;29:1-7. PubMed doi:10.1002/(SICI)1099-0496(200001)29:1<1::AID-PPUL1>3.0.CO;2-1

351. Penić A, Begić D, Balajić K, Kowalski M, Marušić A, Puljak L. Definitions of blinding in randomised controlled trials of interventions

published in high-impact anaesthesiology journals: a methodological study and survey of authors. BMJ Open 2020;10:e035168. PubMed doi:10.1136/bmjopen-2019-035168

352. Lang T. Masking or blinding? An unscientific survey of mostly medical journal editors on the great debate. MedGenMed 2000;2:E25.

PubMed

353. Mills E, Prousky J, Raskin G, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC

Clin Pharmacol 2003;3:4. PubMed doi:10.1186/1472-6904-3-4

354. Bello S, Moustgaard H, Hróbjartsson A. Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials,

unreported loss of blinding in 1 of 10 trials. J Clin Epidemiol 2017;81:42-50. PubMed doi:10.1016/j.jclinepi.2016.08.002

355. Bello S, Moustgaard H, Hróbjartsson A. The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial

publications. J Clin Epidemiol 2014;67:1059-69. PubMed doi:10.1016/j.jclinepi.2014.05.007

356. Hróbjartsson A, Boutron I. Blinding in randomized clinical trials: imposed impartiality. Clin Pharmacol Ther 2011;90:732-6.

PubMed doi:10.1038/clpt.2011.207

357. Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after allocation in randomised controlled trials: survey of published

parallel group trials in obstetrics and gynaecology. BMJ 1996;312:742-4. PubMed doi:10.1136/bmj.312.7033.742

358. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised,

placebo controlled trials. BMJ 2004;328:432. PubMed doi:10.1136/bmj.37952.631667.EE

359. Sackett DL. Turning a blind eye: why we don’t test for blindness at the end of our trials. BMJ 2004;328:1136.

PubMed doi:10.1136/bmj.328.7448.1136-a

360. Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. Lancet 2010;375:1144-6.

PubMed doi:10.1016/S0140-6736(10)60413-8

361. Freeman D, Emsley R, Diamond R, et al; Oxford Cognitive Approaches to Psychosis Trial Study Group. Comparison of a theoretically driven

cognitive therapy (the Feeling Safe Programme) with befriending for the treatment of persistent persecutory delusions: a parallel, single-blind, randomised controlled trial. Lancet Psychiatry 2021;8:696-707. PubMed doi:10.1016/S2215-0366(21)00158-9

362. Wilby MJ, Best A, Wood E, et al. Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica

secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation. Lancet Rheumatol 2021;3:e347-56. PubMed doi:10.1016/S2665-9913(21)00036-9

363. Witham MD, Band M, Ahmed A, et al; BiCARB study group. Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older

patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial. BMC Med 2020;18:91. PubMed doi:10.1186/s12916-020-01542-9

364. Lang TA, Secic M. How to report statistics in medicine: annotated guidelines for authors, editors, and reviewers. Philadelphia: American

College of Physicians; 1997.

365. Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. In: Altman DG, Machin D, Bryant

TN, Gardner MJ, eds. Statistics with Confidence: Confidence Intervals and Statistical Guidelines. 2nd ed. BMJ Books, 2000: 171-90.

366. Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med 1985;4:521-6.

PubMed doi:10.1002/sim.4780040412

367. Bray R, Hartley A, Wenkert D, et al; Medical Outreach Team of the Drug Information Association Bayesian Scientific Working Group. Why

are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers. Ther Innov Regul Sci 2023;57:426-35. PubMed doi:10.1007/s43441-022-00482-1

368. Fors M, González P. Current status of Bayesian clinical trials for oncology, 2020. Contemp Clin Trials Commun 2020;20:100658.

PubMed doi:10.1016/j.conctc.2020.100658

369. Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med 2012;31:2955-72. PubMed doi:10.1002/sim.5404

370. Kahan BC, Jairath V, Doré CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12

outcomes from 8 studies. Trials 2014;15:139. PubMed doi:10.1186/1745-6215-15-139

371. Sullivan TR, Morris TP, Kahan BC, Cuthbert AR, Yelland LN. Categorisation of continuous covariates for stratified randomisation: How

should we adjust? Stat Med 2024;43:2083-95. PubMed doi:10.1002/sim.10060

372. Kahan BC, Rushton H, Morris TP, Daniel RM. A comparison of methods to adjust for continuous covariates in the analysis of randomised

trials. BMC Med Res Methodol 2016;16:42. PubMed doi:10.1186/s12874-016-0141-3

373. Yu LM, Chan AW, Hopewell S, Deeks JJ, Altman DG. Reporting on covariate adjustment in randomised controlled trials before and after

revision of the 2001 CONSORT statement: a literature review. Trials 2010;11:59. PubMed doi:10.1186/1745-6215-11-59

374. Saquib N, Saquib J, Ioannidis JP. Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic

study. BMJ 2013;347:f4313. PubMed doi:10.1136/bmj.f4313

375. Guglieri M, Bushby K, McDermott MP, et al; FOR-DMD Investigators of the Muscle Study Group. Effect of different corticosteroid dosing

regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA 2022;327:1456-68. PubMed doi:10.1001/jama.2022.4315

376. Davies M, Færch L, Jeppesen OK, et al; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and

type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971-84. PubMed doi:10.1016/S0140-6736(21)00213-0

377. André F, Hee Park Y, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive

metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023;401:1773-85. PubMed doi:10.1016/S0140-6736(23)00725-0

378. Freeman J, Hendrie W, Jarrett L, et al. Assessment of a home-based standing frame programme in people with progressive multiple

sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis. Lancet Neurol 2019;18:736-47. PubMed doi:10.1016/S1474-4422(19)30190-5

379. Nüesch E, Trelle S, Reichenbach S, et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-

epidemiological study. BMJ 2009;339:b3244. PubMed doi:10.1136/bmj.b3244

380. Chalmers I, Matthews R, Glasziou P, Boutron I, Armitage P. Trial analysis by treatment allocated or by treatment received? Origins of ‘the

intention-to-treat principle’ to reduce allocation bias: Part 1. J R Soc Med 2023;116:343-50. PubMed doi:10.1177/01410768231203922

381. Chalmers I, Matthews R, Glasziou P, Boutron I, Armitage P. Trial analysis by treatment allocated or by treatment received? Origins of ‘the

intention-to-treat principle’ to reduce allocation bias: Part 2. J R Soc Med 2023;116:386-94. PubMed doi:10.1177/01410768231203936

382. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ

2011;342:d40. PubMed doi:10.1136/bmj.d40

383. Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials 2016;13:161-8. PubMed doi:10.1177/1740774515602688

384. Molnar FJ, Man-Son-Hing M, Hutton B, Fergusson DA. Have last-observation-carried-forward analyses caused us to favour more toxic

dementia therapies over less toxic alternatives? A systematic review. Open Med 2009;3:e31-50. PubMed

385. White IR, Carpenter J, Horton NJ. Including all individuals is not enough: lessons for intention-to-treat analysis. Clin Trials 2012;9:396-407.

PubMed doi:10.1177/1740774512450098

386. Gaughran F, Stringer D, Wojewodka G, et al. Effect of vitamin D supplementation on outcomes in people with early psychosis: the DFEND

randomized clinical trial. JAMA Netw Open 2021;4:e2140858. PubMed doi:10.1001/jamanetworkopen.2021.40858

387. Choudhry NK, Fifer S, Fontanet CP, et al; SPINE CARE Investigators. Effect of a biopsychosocial intervention or postural therapy on

disability and health care spending among patients with acute and subacute spine pain: the SPINE CARE randomized clinical trial. JAMA 2022;328:2334-44. PubMed doi:10.1001/jama.2022.22625

388. Lewis GD, Voors AA, Cohen-Solal A, et al. Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection

fraction: the METEORIC-HF randomized clinical trial. JAMA 2022;328:259-69. PubMed doi:10.1001/jama.2022.11016

​

389. Schlapbach LJ, Gibbons KS, Horton SB, et al; NITRIC Study Group, the Australian and New Zealand Intensive Care Society Clinical Trials

Group (ANZICS CTG), and the ANZICS Paediatric Study Group (PSG). Effect of nitric oxide via cardiopulmonary bypass on ventilator-free days in young children undergoing congenital heart disease surgery: the NITRIC randomized clinical trial. JAMA 2022;328:38-47. PubMed doi:10.1001/jama.2022.9376

390. Akl EA, Shawwa K, Kahale LA, et al. Reporting missing participant data in randomised trials: systematic survey of the methodological

literature and a proposed guide. BMJ Open 2015;5:e008431. PubMed doi:10.1136/bmjopen-2015-008431

391. Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in

major medical journals. Clin Trials 2004;1:368-76. PubMed doi:10.1191/1740774504cn032oa

392. Bell ML, Fiero M, Horton NJ, Hsu C-H. Handling missing data in RCTs; a review of the top medical journals. BMC Med Res Methodol

2014;14:118. PubMed doi:10.1186/1471-2288-14-118

393. Ibrahim F, Tom BDM, Scott DL, Prevost AT. A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and

handling of missing data in composite outcomes. Trials 2016;17:272. PubMed doi:10.1186/s13063-016-1402-5

394. Joseph R, Sim J, Ogollah R, Lewis M. A systematic review finds variable use of the intention-to-treat principle in musculoskeletal randomized

controlled trials with missing data. J Clin Epidemiol 2015;68:15-24. PubMed doi:10.1016/j.jclinepi.2014.09.002

395. Kahale LA, Diab B, Khamis AM, et al. Potentially missing data are considerably more frequent than definitely missing data: a

methodological survey of 638 randomized controlled trials. J Clin Epidemiol 2019;106:18-31. PubMed doi:10.1016/j.jclinepi.2018.10.001

396. Kearney A, Rosala-Hallas A, Rainford N, et al. Increased transparency was required when reporting imputation of primary outcome data in

clinical trials. J Clin Epidemiol 2022;146:60-7. PubMed doi:10.1016/j.jclinepi.2022.02.008

397. Khan NA, Torralba KD, Aslam F. Missing data in randomised controlled trials of rheumatoid arthritis drug therapy are substantial and

handled inappropriately. RMD Open 2021;7:e001708. PubMed doi:10.1136/rmdopen-2021-001708

398. Tan P-T, Cro S, Van Vogt E, Szigeti M, Cornelius VR. A review of the use of controlled multiple imputation in randomised controlled trials with

missing outcome data. BMC Med Res Methodol 2021;21:72. PubMed doi:10.1186/s12874-021-01261-6

399. Zhang Y, Flórez ID, Colunga Lozano LE, et al. A systematic survey on reporting and methods for handling missing participant data for

continuous outcomes in randomized controlled trials. J Clin Epidemiol 2017;88:57-66. PubMed doi:10.1016/j.jclinepi.2017.05.017</jrn>

400. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3-15. PubMed doi:10.1177/096228029900800102</jrn>

401. Kenward MG, Molenberghs G. Last observation carried forward: a crystal ball? J Biopharm Stat 2009;19:872-88.

PubMed doi:10.1080/10543400903105406

402. Morris TP, Kahan BC, White IR. Choosing sensitivity analyses for randomised trials: principles. BMC Med Res Methodol 2014;14:11.

PubMed doi:10.1186/1471-2288-14-11

403. Food and Drug Administration. E9 (R1) statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials.

Guidance for Industry. May 2021.

404. Hussain JA, White IR, Johnson MJ, et al. Development of guidelines to reduce, handle and report missing data in palliative care trials: A

multi-stakeholder modified nominal group technique. Palliat Med 2022;36:59-70. PubMed doi:10.1177/02692163211065597

405. Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ

2009;338:b2393. PubMed doi:10.1136/bmj.b2393

406. Eisenberg MJ, Hébert-Losier A, Windle SB, et al; E3 Investigators. Effect of e-cigarettes plus counseling vs counseling alone on smoking

cessation: a randomized clinical trial. JAMA 2020;324:1844-54. PubMed doi:10.1001/jama.2020.18889

407. Kehoe PG, Turner N, Howden B, et al; RADAR investigators. Safety and efficacy of losartan for the reduction of brain atrophy in clinically

diagnosed Alzheimer’s disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2021;20:895-906. PubMed doi:10.1016/S1474-4422(21)00263-5

408. Knight M, Chiocchia V, Partlett C, et al; ANODE collaborative group. Prophylactic antibiotics in the prevention of infection after operative

vaginal delivery (ANODE): a multicentre randomised controlled trial. Lancet 2019;393:2395-403. PubMed doi:10.1016/S0140-6736(19)30773-1

409. Sandhu HK, Booth K, Furlan AD, et al. Reducing opioid use for chronic pain with a group-based intervention: a randomized clinical trial.

JAMA 2023;329:1745-56. PubMed doi:10.1001/jama.2023.6454

410. Parpia S, Morris TP, Phillips MR, et al; Retina Evidence Trials InterNational Alliance (R.E.T.I.N.A.) Study Group. Sensitivity analysis in clinical

trials: three criteria for a valid sensitivity analysis. Eye (Lond) 2022;36:2073-4. PubMed doi:10.1038/s41433-022-02108-0

411. Williamson SF, Grayling MJ, Mander AP, et al. Subgroup analyses in randomized controlled trials frequently categorized continuous

subgroup information. J Clin Epidemiol 2022;150:72-9. PubMed doi:10.1016/j.jclinepi.2022.06.017

412. Sun X, Briel M, Busse JW, et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials:

systematic review. BMJ 2011;342:d1569. PubMed doi:10.1136/bmj.d1569

413. Paratore C, Zichi C, Audisio M, et al. Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced

solid tumours: a systematic review of trials published between 2017 and 2020. ESMO Open 2022;7:100593. PubMed doi:10.1016/j.esmoop.2022.100593

414. Brand KJ, Hapfelmeier A, Haller B. A systematic review of subgroup analyses in randomised clinical trials in cardiovascular disease. Clin

Trials 2021;18:351-60. PubMed doi:10.1177/1740774520984866

415. Brankovic M, Kardys I, Steyerberg EW, et al. Understanding of interaction (subgroup) analysis in clinical trials. Eur J Clin Invest

2019;49:e13145. PubMed doi:10.1111/eci.13145

416. Wallach JD, Sullivan PG, Trepanowski JF, Steyerberg EW, Ioannidis JP. Sex based subgroup differences in randomized controlled trials:

empirical evidence from Cochrane meta-analyses. BMJ 2016;355:i5826. PubMed doi:10.1136/bmj.i5826

417. Liu P, Ioannidis JPA, Ross JS, et al. Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study. BMC

Med 2019;17:188. PubMed doi:10.1186/s12916-019-1420-8

418. Liu P, Ross JS, Ioannidis JP, Dhruva SS, Vasiliou V, Wallach JD. Prevalence and significance of race and ethnicity subgroup analyses in

Cochrane intervention reviews. Clin Trials 2020;17:231-4. PubMed doi:10.1177/1740774519887148

419. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006;332:1080. PubMed doi:10.1136/bmj.332.7549.1080

420. Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using

fractional polynomials. Stat Med 2004;23:2509-25. PubMed doi:10.1002/sim.1815

421. Beard DJ, Davies LJ, Cook JA, et al; TOPKAT Study Group. The clinical and cost-effectiveness of total versus partial knee replacement in

patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial. Lancet 2019;394:746-56. PubMed doi:10.1016/S0140-6736(19)31281-4

422. Nguyen C, Boutron I, Baron G, et al. Intradiscal glucocorticoid injection for patients with chronic low back pain associated with active

discopathy. Ann Intern Med 2017;166:547-56. PubMed doi:10.7326/M16-1700

423. Egger M, Jüni P, Bartlett C; CONSORT Group (Consolidated Standards of Reporting of Trials). Value of flow diagrams in reports of

randomized controlled trials. JAMA 2001;285:1996-9. PubMed doi:10.1001/jama.285.15.1996

424. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1410-2.

PubMed doi:10.1056/NEJM197912273012602

425. May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. Circulation 1981;64:669-73.

PubMed doi:10.1161/01.CIR.64.4.669

426. Altman DG, Cuzick J, Peto J. More on zidovudine in asymptomatic HIV infection. N Engl J Med 1994;330:1758-9.

PubMed doi:10.1056/NEJM199406163302415

427. Meinert CL. Beyond CONSORT: need for improved reporting standards for clinical trials. Consolidated Standards of Reporting Trials. JAMA

1998;279:1487-9. PubMed doi:10.1001/jama.279.18.1487

428. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med

1987;317:426-32. PubMed doi:10.1056/NEJM198708133170706

429. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older

adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;133:516-26. PubMed doi:10.7326/0003-4819-133-7-200010030-00010

430. Predel HG, Ebel-Bitoun C, Lange R, Weiser T. A randomized, placebo- and active-controlled, multi-country, multi-center parallel group trial

to evaluate the efficacy and safety of a fixed-dose combination of 400 mg ibuprofen and 100 mg caffeine compared with ibuprofen 400 mg and placebo in patients with acute lower back or neck pain. J Pain Res 2019;12:2771-83. PubMed doi:10.2147/JPR.S217045

431. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol 1991;9:191-2. PubMed doi:10.1200/JCO.1991.9.1.191

432. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995;72:511-8.

PubMed doi:10.1038/bjc.1995.364

433. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for

reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298. PubMed doi:10.1371/journal.pmed.0020298

434. Diggle L, Deeks J. Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised

controlled trial. BMJ 2000;321:931-3. PubMed doi:10.1136/bmj.321.7266.931

435. Pocock S, White I. Trials stopped early: too good to be true? Lancet 1999;353:943-4. PubMed doi:10.1016/S0140-6736(98)00379-1

436. Montori VM, Devereaux PJ, Adhikari NKJ, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005;294:2203-9.

PubMed doi:10.1001/jama.294.17.2203

437. Psaty BM, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA 2003;289:2128-31.

PubMed doi:10.1001/jama.289.16.2128

438. Temple R. FDA perspective on trials with interim efficacy evaluations. Stat Med 2006;25:3245-9, discussion 3326-47.

PubMed doi:10.1002/sim.2631

439. Fernandes RM, van der Lee JH, Offringa M. A systematic review of the reporting of Data Monitoring Committees’ roles, interim analysis and

early termination in pediatric clinical trials. BMC Pediatr 2009;9:77. PubMed doi:10.1186/1471-2431-9-77

440. Hahn J-Y, Song YB, Oh J-H, et al; SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on

cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 2019;321:2428-37. PubMed doi:10.1001/jama.2019.8146

441. Liu M, Chen J, Wu Q, Zhu W, Zhou X. Adherence to the CONSORT statement and extension for nonpharmacological treatments in

randomized controlled trials of bariatric surgery: A systematic survey. Obes Rev 2021;22:e13252. PubMed doi:10.1111/obr.13252

442. Gossec L, Tubach F, Dougados M, Ravaud P. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic

diseases: a systematic literature review. Am J Med Sci 2007;334:248-54. PubMed doi:10.1097/MAJ.0b013e318068dde8

443. Zhang Z, Peluso MJ, Gross CP, Viscoli CM, Kernan WN. Adherence reporting in randomized controlled trials. Clin Trials 2014;11:195-204.

PubMed doi:10.1177/1740774513512565

444. Persch AC, Page SJ. Protocol development, treatment fidelity, adherence to treatment, and quality control. Am J Occup Ther 2013;67:146-

53. PubMed doi:10.5014/ajot.2013.006213

445. Beets MW, von Klinggraeff L, Burkart S, et al. Impact of risk of generalizability biases in adult obesity interventions: A meta-epidemiological

review and meta-analysis. Obes Rev 2022;23:e13369. PubMed doi:10.1111/obr.13369

446. Beets MW, Weaver RG, Ioannidis JPA, et al. Identification and evaluation of risk of generalizability biases in pilot versus

efficacy/effectiveness trials: a systematic review and meta-analysis. Int J Behav Nutr Phys Act 2020;17:19. PubMed doi:10.1186/s12966-020-0918-y

447. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, 

randomised controlled trial. BMJ 2020;369:m1849. PubMed doi:10.1136/bmj.m1849

448. Sackett DL. Clinician-trialist rounds: 5. Cointervention bias--how to diagnose it in their trial and prevent it in yours. Clin Trials 2011;8:440-2.

PubMed doi:10.1177/1740774511410995

449. Higgins JPT, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane

Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. PubMed doi:10.1136/bmj.d5928

450. Moutzouri E, Adam L, Feller M, et al. Low reporting of cointerventions in recent cardiovascular clinical trials: a systematic review. J Am Heart

Assoc 2020;9:e014890. PubMed doi:10.1161/JAHA.119.014890

451. Bührer J, Del Giovane C, Gencer B, et al. Inadequate reporting of cointerventions, other methodological factors, and treatment estimates in

cardiovascular trials: a meta-epidemiological study. Mayo Clin Proc Innov Qual Outcomes 2023;7:231-40. PubMed doi:10.1016/j.mayocpiqo.2023.04.010

452. Iudici M, Riveros C, Gabay C, Puéchal X, Berthelot JM, Ravaud P. Inadequate reporting of concomitant medications in rheumatology

randomized controlled trials of pharmacologic interventions. Semin Arthritis Rheum 2019;49:453-8. PubMed doi:10.1016/j.semarthrit.2019.03.009

453. Lamb SE, Williamson EM, Heine PJ, et al; Strengthening and Stretching for Rheumatoid Arthritis of the Hand Trial (SARAH) Trial Team.

Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. Lancet 2015;385:421-9. PubMed doi:10.1016/S0140-6736(14)60998-3

454. Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P; CONSORT-Equity and Boston Equity Symposium. CONSORT-Equity 2017

extension and elaboration for better reporting of health equity in randomised trials. BMJ 2017;359:j5085. PubMed doi:10.1136/bmj.j5085

455. Senn SJ. Base logic: tests of baseline balance in randomized clinical trials. Clin Res Regul Aff 1995;12:171-82

doi:10.3109/10601339509019426.

456. Austin PC, Manca A, Zwarenstein M, Juurlink DN, Stanbrook MB. A substantial and confusing variation exists in handling of baseline

covariates in randomized controlled trials: a review of trials published in leading medical journals. J Clin Epidemiol 2010;63:142-53. PubMed doi:10.1016/j.jclinepi.2009.06.002

457. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting:

current practice and problems. Stat Med 2002;21:2917-30. PubMed doi:10.1002/sim.1296

458. de Boer MR, Waterlander WE, Kuijper LDJ, Steenhuis IHM, Twisk JWR. Testing for baseline differences in randomized controlled trials: an

unhealthy research behavior that is hard to eradicate. Int J Behav Nutr Phys Act 2015;12:4. PubMed doi:10.1186/s12966-015-0162-z

459. Altman DG. Comparability of randomised groups. Statistician 1985;34:125-36 doi:10.2307/2987510.

460. Beard DJ, Davies L, Cook JA, et al; ACL SNNAP Study Group. Rehabilitation versus surgical reconstruction for non-acute anterior cruciate

ligament injury (ACL SNNAP): a pragmatic randomised controlled trial. Lancet 2022;400:605-15. PubMed doi:10.1016/S0140-6736(22)01424-6

461. Sola A, Kurlat I, Pollak A, et al. Early versus delayed neonatal administration of a synthetic surfactant--the judgment of OSIRIS. The OSIRIS

Collaborative Group (open study of infants at high risk of or with respiratory insufficiency--the role of surfactant. Lancet 1992;340:1363-9. PubMed doi:10.1016/0140-6736(92)92557-V

462. Hussain JA, White IR, Langan D, et al. Missing data in randomized controlled trials testing palliative interventions pose a significant risk of

bias and loss of power: a systematic review and meta-analyses. J Clin Epidemiol 2016;74:57-65. PubMed doi:10.1016/j.jclinepi.2015.12.003

463. Altman DG. Clinical trials and meta-analyses. In: Altman DG, Machin D, Bryant DM, Gardner MJ, eds. Statistics with confidence. 2nd ed. BMJ

Books, 2000: 120-38.

464. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Ann Intern

Med 1997;126:36-47. PubMed doi:10.7326/0003-4819-126-1-199701010-00006

465. Altman DG. Confidence intervals in practice. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence. 2nd ed. BMJ

Books, 2000: 6-14.

466. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed)

1986;292:746-50. PubMed doi:10.1136/bmj.292.6522.746

467. Bailar JC 3rd, Mosteller F. Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. Ann Intern

Med 1988;108:266-73. PubMed doi:10.7326/0003-4819-108-2-266

468. Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias.

PLoS One 2008;3:e3081. PubMed doi:10.1371/journal.pone.0003081

469. Sorensen L, Gyrd-Hansen D, Kristiansen IS, Nexøe J, Nielsen JB. Laypersons’ understanding of relative risk reductions: randomised cross-

sectional study. BMC Med Inform Decis Mak 2008;8:31. PubMed doi:10.1186/1472-6947-8-31

470. Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effect on physicians’ willingness to prescribe. Lancet

1994;343:1209-11. PubMed doi:10.1016/S0140-6736(94)92407-4

471. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic

effectiveness? Ann Intern Med 1992;117:916-21. PubMed doi:10.7326/0003-4819-117-11-916

472. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4. PubMed

doi:10.1136/bmj.310.6977.452

473. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-5.

PubMed doi:10.1136/bmj.319.7223.1492

474. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol

2006;24:3933-8. PubMed doi:10.1200/JCO.2005.05.3959

475. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med

2009;169:1756-61. PubMed doi:10.1001/archinternmed.2009.306

476. Williams MR, McKeown A, Pressman Z, et al. Adverse event reporting in clinical trials of intravenous and invasive pain treatments: an

ACTTION systematic review. J Pain 2016;17:1137-49. PubMed doi:10.1016/j.jpain.2016.07.006

477. Mayo-Wilson E, Qureshi R, Hong H, Chen X, Li T. Harms were detected but not reported in six clinical trials of gabapentin. J Clin Epidemiol

2023;164:76-87. PubMed doi:10.1016/j.jclinepi.2023.10.014

478. Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov

and published in journals. PLoS Med 2013;10:e1001566, discussion e1001566. PubMed doi:10.1371/journal.pmed.1001566

479. Jain A, Greig AVH, Jones A, et al; NINJA Collaborative. Effectiveness of nail bed repair in children with or without replacing the fingernail:

NINJA multicentre randomized clinical trial. Br J Surg 2023;110:432-8. PubMed doi:10.1093/bjs/znad031

480. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977;198:679-84. PubMed

doi:10.1126/science.333584

481. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-

9. PubMed doi:10.1016/S0140-6736(00)02039-0

482. Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann Intern Med 1992;116:78-84. PubMed doi:10.7326/0003-4819-116-1-

78

483. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical

trials. JAMA 1991;266:93-8. PubMed doi:10.1001/jama.1991.03470010097038

484. Hahn S, Williamson PR, Hutton JL, Garner P, Flynn EV. Assessing the potential for bias in meta-analysis due to selective reporting of

subgroup analyses within studies. Stat Med 2000;19:3325-36. PubMed doi:10.1002/1097-0258(20001230)19:24<3325::AID-SIM827>3.0.CO;2-D

485. Bhandari M, Devereaux PJ, Li P, et al. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res

2006;447:247-51. PubMed doi:10.1097/01.blo.0000218736.23506.fe

486. Horton R. The rhetoric of research. BMJ 1995;310:985-7. PubMed doi:10.1136/bmj.310.6985.985

487. Boutron I, Altman DG, Hopewell S, Vera-Badillo F, Tannock I, Ravaud P. Impact of spin in the abstracts of articles reporting results of

randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. J Clin Oncol 2014;32:4120-6. PubMed doi:10.1200/JCO.2014.56.7503

488. Checketts JX, Riddle J, Zaaza Z, Boose MA, Whitener JH, Vassar MB. An evaluation of spin in lower extremity joint trials. J Arthroplasty

2019;34:1008-12. PubMed doi:10.1016/j.arth.2019.01.016

489. Austin J, Smith C, Natarajan K, Som M, Wayant C, Vassar M. Evaluation of spin within abstracts in obesity randomized clinical trials: A cross-

sectional review. Clin Obes 2019;9:e12292. PubMed doi:10.1111/cob.12292

490. Clarke M, Hopewell S, Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant

evidence: a status report. J R Soc Med 2007;100:187-90. PubMed doi:10.1177/014107680710011415

491. Glasziou P, Jones M, Clarke M. Setting new research in the context of previous research: some options. BMJ Evid Based Med 2024;29:44-6.

PubMed doi:10.1136/bmjebm-2023-112300

492. Hoffmann F, Allers K, Rombey T, et al. Nearly 80 systematic reviews were published each day: Observational study on trends in

epidemiology and reporting over the years 2000-2019. J Clin Epidemiol 2021;138:1-11. PubMed doi:10.1016/j.jclinepi.2021.05.022

493. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial

results. Cochrane Database Syst Rev 2009;2009:MR000006. PubMed

494. Avidan MS, Ioannidis JPA, Mashour GA. Independent discussion sections for improving inferential reproducibility in published research. Br J

Anaesth 2019;122:413-20. PubMed doi:10.1016/j.bja.2018.12.010

495. Boden WE, O’Rourke RA, Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary

disease. N Engl J Med 2007;356:1503-16. PubMed doi:10.1056/NEJMoa070829

496. Purcell GP, Donovan SL, Davidoff F. Changes to manuscripts during the editorial process: characterizing the evolution of a clinical paper.

JAMA 1998;280:227-8. PubMed doi:10.1001/jama.280.3.227

497. Annals of Internal Medicine. Information for authors 2008 https://www.annals.org/ [Accessed 15 January 2008].</eref>

498. Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ 1999;318:1224-5. PubMed

doi:10.1136/bmj.318.7193.1224

499. The BMJ. Article types and preparation. https://www.bmj.com/about-bmj/resources-authors/article-types [Accessed 18 January 2024] 2024

500. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485. PubMed doi:10.1136/bmj.311.7003.485

501. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials 2006;1:e9.

PubMed doi:10.1371/journal.pctr.0010009

502. Chauvin A, Ravaud P, Moher D, et al. Accuracy in detecting inadequate research reporting by early career peer reviewers using an online

CONSORT-based peer-review tool (COBPeer) versus the usual peer-review process: a cross-sectional diagnostic study. BMC Med 2019;17:205. PubMed doi:10.1186/s12916-019-1436-0

Reference 1
Reference25
Reference 2
Reference 3
Reference 4
Reference 5
Reference 6
Reference 7
Reference 8
Reference 10
Reference 9
Reference 11
Reference 12
Reference 13
Reference 14
Reference 15
Reference 16
Reference 17
Reference 18
Reference 19
Reference 20
Reference 21
Reference 22
Reference 23
Reference 24
Reference 26
Reference 27
Reference 28
Reference 29
Reference 30
Reference 31
Reference 32
Reference 33
Reference 34
Reference 35
Reference 36
Reference 37
Reference 38
Reference 39
Reference 40
Reference 41
Reference 42
Ref 43
Ref 44
Ref 45
Ref 46
Ref 47
Ref 48
Ref 49
Ref 50
Ref 51
Ref 52
Ref 53
Ref 54
Ref 55
Ref 56
Ref 57
Ref 58
Ref 59
Ref 60
Ref 61
Ref 62
Ref 63
Ref 64
Ref 65
Ref 66
Ref 67
Ref 68
Ref 69
Ref 70
Ref 71
Ref 72
Ref 73
Ref 74
Ref 75
Ref 76
Ref 77
Ref 78
Ref 79
Ref 80
Ref 81
Ref 82
Ref 83
Ref 84
Ref 85
Ref 86
Ref 87
Ref 88
Ref 89
Ref 90
Ref 91
Ref 92
Ref 93
Ref 94
Ref 95
Ref 96
Ref 97
Ref 98
Ref 99
Ref 100
Ref 101
Ref 102
Ref 103
Ref 104
Ref 105
Ref 106
Ref 107
Ref 108
Ref 109
Ref 110
Ref 111
Ref 112
Ref 113
Ref 114
Ref 115
Ref 116
Ref 117
Ref 118
Ref 119
Ref 120
Ref 121
Ref 122
Ref 123
Ref 124
Ref 125
Ref 126
Ref 127
Ref 128
Ref 129
Ref 130
Ref 131
Ref 132
Ref 133
Ref 134
Ref 135
Ref 136
Ref 137
Ref 138
Ref 139
Ref 140
Ref 141
Ref 142
Ref 143
Ref 144
Ref 145
Ref 146
Ref 147
Ref 149
Ref 148
Ref 150
Ref 151
Ref 152
Ref 153
Ref 154
Ref 155
Ref 156
Ref 157
Ref 158
Ref 159
Ref 160
Ref 161
Ref 162
Ref 163
Ref 164
Ref 165
Ref 166
Ref 167
Ref 168
Ref 169
Ref 170
Ref 171
Ref 172
Ref 173
Ref 174
Ref 175
Ref 176
Ref 177
Ref 178
Ref 179
Ref 180
Ref 181
Ref 182
Ref 183
Ref 184
Ref 185
Ref 187
Ref 188
Ref 189
Ref 190
Ref 191
Ref 192
Ref 193
Ref 194
Ref 195
Ref 196
Ref 197
Ref 198
Ref 199
Ref 200
Ref 201
Ref 202
Ref 203
Ref 204
Ref 205
Ref 206
Ref 207
Ref 208
Ref 209
Ref 210
Ref 211
Ref 212
Ref 213
Ref 214
Ref 215
Ref 216
Ref 217
Ref 218
Ref 219
Ref 220
Ref 221
Ref 222
Ref 223
Ref 224
Ref 225
Ref 226
Ref 227
Ref 228
Ref 229
Ref 230
Ref 231
Ref 232
Ref 233
Ref 234
Ref 235
Ref 236
Ref 237
Ref 238
Ref 239
Ref 240
Ref 241
Ref 242
Ref 243
Ref 244
Ref 245
Ref 246
Ref 247
Ref 248
Ref 249
Ref 250
Ref 251
Ref 252
Ref 253
Ref 254
Ref 255
Ref 256
Ref 257
Ref 258
Ref 259
Ref 260
Ref 261
Ref 262
Ref 263
Ref 264
Ref 265
Ref 266
Ref 267
Ref 268
Ref 269
Ref 270
Ref 271
Ref 272
Ref 273
Ref 274
Ref 275
Ref 276
Ref 277
Ref 278
Ref 279
Ref 280
Ref 281
Ref 282
Ref 283
Ref 284
Ref 285
Ref 286
Ref 287
Ref 288
Ref 289
Ref 290
Ref 291
Ref 292
Ref 293
Ref 294
Ref 295
Ref 296
Ref 297
Ref 298
Ref 299
Ref 300
Ref 301
Rf 302
Rf 303
Rf 304
Ref 305
Ref 306
Ref 307
Ref 308
Ref 309
Ref 310
Ref 311
Ref 312
Ref 313
Ref 315
Ref 314
Ref 316
Ref 317
Ref 318
Ref 319
Ref 320
Ref 321
Ref 322
Ref 323
Ref 324
Ref 325
Ref 326
Ref 327
Ref 328
Ref 329
Ref 330
Ref 331
Ref 332
Ref 333
Rf 334
Ref 335
Ref 336
Ref 337
Ref 338
Ref 339
Ref 340
Ref 341
Ref 342
Ref 343
Ref 344
Ref 345
Ref 346
Ref 347
Ref 348
Ref 349
Ref 350
Ref 351
Ref 352
Rf 353
Ref 354
Ref 356
Ref 357
Ref 358
Ref 359
Ref 360
Ref 361
Ref 362
Ref 363
Ref 364
Ref 365
Ref 366
Ref 367
Ref 368
Ref 369
Ref 370
Ref 371
Ref 372
Ref 373
Ref 374
Ref 375
Ref 376
Ref 377
Ref 378
Ref 379
Ref 380
Ref 381
Ref 382
Ref 383
Ref 384
Ref 385
Ref 386
Ref 387
Ref 388
Ref 389
Ref 390
Ref 391
Ref 392
Ref 393
Ref 394
Ref 395
Ref 396
Ref 397
Ref 398
Ref 399
Ref 400
Ref 401
Ref 402
Ref 403
Ref 404
Ref 405
Ref 406
Ref 407
Ref 408
Ref 409
Ref 410
Ref 411
Ref 412
Ref 413
Ref 414
Ref 415
Ref 416
Ref 417
Ref 418
Ref 419
Ref 420
Ref 421
Ref 422
Ref 423
Ref 424
Ref 425
Ref 426
Ref 427
Ref 429
Ref 430
Ref 431
Ref 432
Ref 433
Ref 434
Ref 435
Ref 436
Ref 437
Ref 438
Ref 439
Ref 440
Ref 441
Ref 442
Ref 443
Ref 444
Ref 445
Ref 446
Ref 447
Ref 448
Ref 449
Ref 450
Ref 451
Ref 452
Ref 453
Ref 454
Ref 455
Ref 456
Ref 457
Ref 458
Ref 459
Ref 460
Ref 461
Ref 462
Ref 463
Ref 464
Ref 465
Ref 466
Ref 467
Ref 468
Ref 469
Ref 470
Ref 471
Ref 472
Ref 474
Ref 475
Ref 476
Ref 477
Ref 478
Ref 479
Ref 480
Ref 481
Ref 482
Ref 483
Ref 484
Ref 485
Ref 486
Ref 487
Ref 488
Ref 489
Ref 490
Ref 491
Ref 492
Ref 493
Ref 494
Ref 495
Ref 496
Ref 497
Ref 498
Ref 499
Ref 500
Ref 501
Ref 502
Logo: jointly funded by the UKRI Medical Research Council and the NIHR (National Institute for Health and Care Research)
University of Oxford logo
University of Toronto logo
The University of North Carolina at Chapel Hill logo
University of Southern Denmark (SDU) logo
University of Ottawa (uOttawa) logo
Université Paris Cité (UPC) logo

The 2025 update of SPIRIT and CONSORT, and this website, are funded by the MRC-NIHR: Better Methods, Better Research [MR/W020483/1]. The views expressed are those of the authors and not necessarily those of the NIHR, the MRC, or the Department of Health and Social Care.

Accessibility |  Terms of use  |  Privacy  |  Site map

bottom of page